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ABSTRACT 
Myra Grace A. dela Peña: CD4+ T cells in Infant Immunity 
(Under the direction of Kristina Abel, PhD) 
 
 
Age and immune maturation are interdependent and dynamic processes. The infant 
immune system undergoes many developmental changes after birth, and compared to adults, 
cellular and molecular differences have been observed in infant immune responses. This 
dissertation is focused on the functional features of CD4+ T helper cells, as these cells are 
critical players in adaptive immunity. In general, infants show a bias toward CD4+ T helper 2 
(Th2) responses, whereas adults generate Th1 responses against infectious diseases caused by 
intracellular pathogens. The infant’s Th2 bias is reflected in increased susceptibility to 
infectious pathogens, and higher morbidity and mortality rates. We hypothesized that 
reduced functionality of infant CD4+ T cells would be due to intrinsic differences in the 
CD4+ T cell signaling that alters responsiveness of these cells, and thereby influences 
maturation, function and the generation of protective immunity. Specifically, we sought to i) 
characterize the immune development of CD4+ T cells in infants, (ii) determine infant CD4+ 
T cell response to exogenous cytokine stimulations, and (iii) assess the effectiveness of infant 
immunity in the control of a viral infection.  
	  	   iv	  
First, we used rhesus macaques raised as specific pathogen free (SPF) and 
conventional status (non-SPF) to characterize basic immunological changes in peripheral 
blood cell populations with age and how they are affected by chronic cytomegalovirus 
infection (RhCMV). Our findings indicated that some age-related changes in major blood 
cell populations from birth to adulthood were common to both SPF and non-SPF macaques.  
We also demonstrated that chronic RhCMV infection modulated immune development over 
the lifetime of the host, evident in a more inflammatory response of juvenile RhCMV-
infected macaques compared to SPF-juveniles. Second, we investigated the functional 
capacity of the infant immune system to control viral replication. We found that infant rhesus 
macaques were rapidly infected with RhCMV via the oral route and shed virus more 
frequently in bodily fluids and in higher titers when compared to adult macaques. Lastly, we 
used cross sectional human blood samples to test the hypothesis that the propensity towards 
Th2 response in infants is due to altered cytokine-receptor mediated signaling in CD4+ T 
cells. Our data showed that CD4+ T cells from cord blood (CB) and older infants differed in 
Th1 and Th2-associated cytokine receptor expression from adults. We also found that 
cytokine-signaling factors (JAKs and STATs) were differentially phosphorylated after 
cytokine treatment. Lastly, in vitro stimulation through the TCR and exogenous addition of 
IFNγ revealed differences in JAK/STAT related gene expression and cytokine productions 
between CB and adult CD4+ T cells. Together, our findings imply that cytokine signaling is 
developmentally controlled because responsiveness to cytokines increased with age in infant 
CD4+ T cells. 
The assessment of important functional parameters in CD4+ T cell development, such 
as cytokine and TCR signaling, from birth to adulthood can reveal mechanistic insights into 
	  	   v	  
how and why cellular immunity changes with age. How lifelong infections and other 
perturbation affect these immunological processes will likely impact both disease outcome 
and the generation of immunity. Unraveling the molecular mechanisms involved in these 
processes may aid in pediatric vaccine designs and therapeutic interventions. 
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CHAPTER 1: GENERATION OF INFANT CD4+ T CELL IMMUNITY 
 
Introduction 
 
The immune system is designed to protect the host from infectious diseases. In an 
infant environment, the immune system is faced with unique challenges because once born, 
the infant encounters a world full of novel microorganisms, pathogens and environmental 
substances. When confronted with these novel antigens of self or foreign origin, the infant 
must establish tolerance to self-antigens (Ags), but also be capable of mobilizing the immune 
system quickly to mount a protective response against infectious agents. Compared to adults, 
cellular and molecular differences have been observed in infant immune responses. These 
altered, generally lower, responses are reflected in the infant’s increased susceptibility to 
infectious pathogens, and in higher morbidity and mortality rates.  
 The focus of this work is to discuss the features of CD4+ T cell responses in infants 
and how they influence the generation of protective immunity. Specifically, the goals of my 
research were to (i) characterize the immune development of CD4+ T cells in infants, (ii) 
determine infant CD4+ T cell response to exogenous cytokine stimulations, and (iii) assess 
the effectiveness of infant immunity in the control of a viral infection.  
Chapter 1 will examine the background behind CD4+ T cell development, 
differentiation and their role in antiviral immunity. The subsequent chapters will discuss in 
more detail the phenotypic and functional changes in infant CD4+ T cells using cross-
sectional human blood samples and longitudinal blood samples collected from rhesus 
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macaque infants during the first year of life. My data from these studies confirm that infant 
CD4+ T cells show altered cytokine responses compared to adults after both polyclonal and 
TCR-mediated T cell activation (Chapter 2). Furthermore, I could evaluate how the infant 
immune responses changed from birth throughout the first year of life in the context of a 
chronic viral infection (Chapter 3). To define the underlying molecular mechanisms for these 
age-specific differences, I examined infant CD4+ T cell signaling in response to various 
cytokines. Indeed, I was able to identify differences in interleukin (IL) signaling, specifically, 
interferon gamma (IFNγ), IL4 and IL2 signaling of infant compared to adult CD4+ T cells 
(Chapter 4). The understanding of the kinetics of immune maturation in infants on the 
molecular level should provide valuable insights for pediatric vaccine design and 
implementation. 
CD4+ T cell development and function in infants 	  
CD4+ T cells originate from pluripotent hematopoietic stem cell precursors found in 
the fetal liver. These precursor cells populate the fetal thymus and will differentiate into 
distinct cell population during thymopoiesis, with the majority of cells developing into T 
cells bearing the αβ T cell receptor (TCR)(21), (25). These T cells can be further classified 
by the presence of specific co-receptors into CD4 or CD8 T cells. Studies show that 
commitment to CD4+ or CD8+ T cell require the kinases Lck or Zap70 for their development 
and peptide recognition through MHC class II or I complexes, respectively (6). Both T cell 
populations undergo proliferative expansion in the periphery to maintain clonal size and 
repertoire (129).  
CD4+ T helper cells (Th) play a central role in effectively orchestrating different 
immune cells to generate an appropriate immune response to protect the host from infections 
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and simultaneously, control the response to avoid detrimental outcomes such as 
autoimmunity. The classic functions of CD4+ Th cells are (1) to promote antibody production 
by B cells, (2) to activate and maintain cytotoxic CD8+ T cells and (3) direct effector 
function via the production of specific cytokines (166), (137). Other non-helper functions of 
CD4+ T cells include activation of macrophage (MΦ) and the regulation and recruitment of 
immune cells (e.g. neutrophils) (57), (43).  Numerous studies have shown that the functional 
capacity of infant CD4+ T cells differs from that of adults (4), (115), (164). The reasons for 
impaired infant CD4+ T cell function, however, have not been fully elucidated. Altered CD4+ 
T cell responses in infants compared to adults could be due to inefficient priming by antigen-
presenting cells (APCs), CD4+ T cell intrinsic factors that prevent optimal activation of their 
responses, or could be the result of active suppression by regulatory cells. In fact, regulatory 
CD4+ T cells are more abundant in infants than in adults (56), (160), (52). Similarly, it has 
been demonstrated that pathogen-recognition receptors (PRRs) such as Toll-like receptors 
(TLRs), are expressed at lower levels on infant compared to adult APCs (72, 79), (24).  The 
differentiation of naïve CD4+ T cells towards a specific Th lineage and effector function 
further depends on the presence of specific cytokines. Infant CD4+ T cell responses are 
generally thought of as Th2 biased, meaning that infant CD4+ T cells are more prone to 
produce IL4, IL5, or IL13 than IFNγ, the characteristic cytokine of Th1 CD4+ T cells. 
Consistent with this observation, it has been shown that the IFNγ promoter in infant CD4+ T 
cells is hyper-methylated compared to adult CD4+ T cells (154, 155). Lower production of 
effector cytokines might increase the vulnerability of infants to infections and delay pathogen 
clearance.  
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The analysis of the phenotype and function of CD4+ T cells in the periphery can 
provide information on an infant’s immunological status. Longitudinal studies on 
lymphocyte populations during the first year of life revealed age-related changes in the CD4+ 
T cell compartment. In healthy children, absolute CD4+ T cell numbers increased during the 
first months of life and decreased around 9 to 15 months of age (126). The circulating infant 
CD4+ T cells, when compared to adults, were found to be recent thymic emigrants, 
phenotypically resembled adult naïve T cells, and were highly sensitive to growth-promoting 
cytokines (129) (126), (142), (74). Interestingly, while effector memory CD4+ T cells were 
absent in umbilical cord blood (CB), CD4+ T cells with a central memory phenotype were 
easily detected at birth and this population remained relatively stable post-birth (126). A 
more detailed analysis of CB revealed that the predominantly naïve infant CD4+ T cells 
expressed less CD45RA, and that the central memory CD4+ T cells might represent a 
transitional phenotype(119). When assessed for function, these infant naïve CD4+ T cells 
(CD45RA+) required longer duration of T cell receptor (TCR) engagement compared to 
mature or Ag-primed (memory; CD45RO+) CD4+ T cells. In the presence of polarizing 
cytokines, infant CD4+ T cells up-regulated CD45RA similar to that of adult levels (37). 
Additional research showed that during secondary stimulations, naïve CB CD45RA+ cells 
differentiated more quickly than their adult counterparts into functionally equivalent 
CD45RO+ T cells supposedly counteracting their slower response after primary stimulation 
(119). Naïve CD4+ CD45RA+ and memory CD4+ CD45RO+ T cells differ in their early 
signal transduction events, suggesting a role of the different isoforms of CD45 and other 
associated proteins (53). Indeed, TCR specific stimulations of purified naïve CB CD4+ 
CD45RA+ resulted in proliferation, but also in more cell death compared to adults, further 
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underlining the distinct responses of infant T cells (26). Determining the functional fates of 
these subset of cells will aid in understanding key differences in the development of infant 
and adult effector and memory CD4+ T cell populations.  
Differentiation of distinct effector CD4+ T cell lineages 	  
The immune system encounters a myriad of microorganisms and appropriate 
generation of effector CD4+ T cells is crucial to achieve protective immunity. The process of 
effector differentiation in CD4+ T cells has been shown to be influenced by the “priming 
conditions”; that is the nature of the pathogen and the cytokine milieu provided by the cells 
of the innate immune system in response to a specific pathogen (166, 167). The different 
CD4+ T cell lineages arise from common precursors, naïve CD4+ T cells that have emerged 
from the thymus and are circulating in the periphery but have not yet encountered their 
cognate antigen(s) (Ags). APCs, e.g. dendritic cells will recognize pathogen-associated 
molecular patterns (PAMPs) derived from microbial proteins via PRRs, express co-
stimulatory ligands and present the Ag-peptides complexed to MHC class II to naïve CD4+ T 
cells. Once naïve CD4+ T cells encounter their cognate Ags through their specific T cell 
receptors (TCRs), they get activated, proliferate, undergo multiple rounds of cell division and 
differentiate into distinct, yet plastic, lineages (Table 1). Decades of research have 
determined that naïve CD4+ T cell precursors must undergo many steps of cell division and 
that differentiation is determined by many factors including antigen dosage, type and 
duration of exposure and the cytokine milieu, before these cells can acquire the effector 
function necessary for their specific function (136). In addition, the strength of the TCR 
signaling influences T cell differentiation (144). Weak TCR stimulation induces a calcium 
signal that triggers IL4- synthesis while stronger TCR stimulation induces mitogen-
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protein kinase (MAPK) that control IFNγ production (11). Moreover, during Ag encounter, 
naïve CD4+ T cells must be exposed to IL2 to sustain cell division and differentiation 
towards highly differentiated effector cells. Defects in IL2 production will result in poor 
generation of effector and memory cells (136).  
Originally, only two distinct CD4+ T cell lineages, Th1 and Th2 were identified (166). 
Now, at least 3 more Th lineages have been discovered (Table 1), with their unique functions 
being primarily determined by the cytokine patterns they produce (99), (167), (51). The 
cellular identity of these differentiated CD4+ T cell lineages is achieved through epigenetic 
changes, where specific and heritable pattern of gene expression are imposed on cells and its 
progeny without changing the DNA sequence (8). Specifically, the identity of these CD4+ T 
cells is controlled by complex dynamic interplays of transcription networks and epigenetic 
modifications such as cis-regulatory DNA elements that affect binding of transcription 
factors, chromatin remodeling and transcription of genes (8). Intriguingly, there is great 
flexibility in the CD4+ T cell commitment to a certain effector T cell subset (20), (99), (86). 
Table 1 below summarizes the main criteria that distinguish the different CD4+ T helper cell 
lineages. 
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Table 1: CD4+ T cell Populations 
 
Pioneering studies demonstrated that unresponsiveness in the infant T cells was 
similar to T cell tolerance to self-Ags, where T cells are educated not to react to self-Ags and 
was termed neonatal tolerance (164). However, there is increasing evidence that infants are 
immunocompetent, and other effector CD4+ T cell populations, including Th1 CD4+ T cells 
can develop. Under appropriate conditions, infant CD4+ T cells showed competence in 
producing cytokines related to Th1 and Th2 when stimulated through the TCR (30). Other 
studies reported that even when CB naïve CD4+ T cells were stimulated with myeloid-
dendritic cells (mDCs) derived from adult monocytes, they showed a lower activation profile 
and impaired Th1 differentiation (impaired IL12 expression, and signaling molecule, 
STAT4) compared to naïve CD4+ T cells from adult peripheral blood (28). The mechanisms 
for neonatal tolerance and immune deviation are still elusive but research in neonatal mice 
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showed that wild type, Stat4-deficient (IL12-Th1 development), and Stat6-deficient mice 
(Th2 development) efficiently established tolerance regardless of immune deviation (27). 
The classification of Th responses into Th1 and Th2 has great historical relevance in infant 
immunity, as the infant immune response is generally considered to have a Th2 type. The 
caveat remains though that even when appropriately stimulated infant CD4+ T cells will 
respond but the response might not be suitable to effectively combat infections. 
 Th1 cells were one of two T helper lineages first discovered in 1986 by Timothy 
Mossman and Robert Coffman (20), (96). These cells protect the hosts against intracellular 
pathogens such as viruses and mycobacteria. IL12 produced by DCs and MΦ is the main 
cytokine that drives the development of Th1 cells.  Surface markers such as IL12Rβ2, 
CXCR3 and CCR5 identify these CD4+ Th1 cells as well as the transcription factors T-bet, 
Eomes and STAT1. Th1 cells mainly produce IFNγ, but also secrete IL2, TNFα and 
lymphotoxin α (166), (167), (139). IFNγ, a pleiotropic cytokine, activates MΦ and increases 
their phagocytic and microbicidal activity (166), (130). Not only is IFNγ the major product of 
Th1 cells, it is also sufficient to further support Th1 development as it maintains 
responsiveness to IL12 along with strong TCR signals in co-stimulation with CD28 and IFNγ 
secreted from innate cells (151). A strong Th1 response translates into effective control of 
intracellular pathogens while aberrant responses result in organ destruction seen in 
autoimmune disorders. Infants have been described to have lower Th1 responses compared to 
adults making them vulnerable to many infectious diseases early in life. Studies on infant 
immune responses to vaccines and pathogens like human cytomegalovirus (HCMV) revealed 
that some functions of their immune system are comparable to adults such as the CD8+ T cell 
response but their ability to mount a protective Th1 response is defective, due to lower IFNγ 
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production by their CD4+ T cells (87). HCMV infected children, whether they acquired the 
virus in utero or during infancy, have low proliferative and IFNγ responses against HCMV 
antigens, and show prolonged excretion of the virus in bodily fluids. Nevertheless, the 
immune system of neonatal mice and humans is not deficient, but altered, and potent Th1 
response, e.g. in response to vaccination of Mycobacterium bovis Bacillus Calmette-Guerin 
(BCG) vaccine, can develop (106). The mechanisms responsible for variable Th1 responses 
against different pathogens are not understood.  
Th2 responses are thought to protect the host against extracellular pathogens (e.g. 
bacteria and helminthes). Their signature cytokine products include IL4, IL5 and IL13, and 
they express the transcription factors Gata-3, c-maf and STAT6. Although the main function 
of Th2 cells is supposed to be in the control of humoral immunity, there is increasing 
evidence that IL4 and IL13 can activate MΦ (166), (167), (146). These so-called alternatively 
activated MΦ are important in homeostasis and tissue repair. Uncontrolled Th2 responses can 
result in allergy and asthma, and are associated with elevated IgE, eosinophilia, increased 
mucus production and smooth muscle hyper-contractility (146). Early studies in neonatal 
mice suggested that that neonatal T cell response was skewed towards the Th2-lineage (4), 
(3). It was also demonstrated that the Th2 cytokine IL4 could utilize an alternative receptor, 
IL13Rα1, in mice and drive apoptosis of Th1 cells (78). Although neonatal mice developed 
both Th1 and Th2 responses during the primary response in this system, the recall response 
was Th2-driven and the Th1 cells underwent apoptosis.  
CD4+ Th17 cells were first described in 2003 and are characterized by the expression 
of the transcription factor RORγt, production of the chemokine CCL20 and the cytokines 
IL17A and F, and IL22 (167), (159). In contrast to mice where the development of Th17 is 
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contingent on TGFβ and IL6, IL23 and IL1β are needed for their induction in humans. 
Although Th17 responses are associated with the development of autoimmune disorders such 
as multiple sclerosis (MS), psoriasis and rheumatoid arthritis (RA), they also confer 
protection against both bacteria and fungi, especially at epithelial surfaces by regulating 
innate immunity (159), (33). Recent studies have shown that the infant immune environment 
is capable of inducing Th17 differentiation and this capacity is achieved within the first three 
months of life (39). The delay in Th17 differentiation might be due to intrinsic mechanisms 
that result in reduced production of RORC2 mRNA, affecting the regulation of RORγt 
expression (35). Other studies reported that development of Th17-lineage capacity was 
inversely correlated with developmental age.  Infant but not adult naïve CD4+ T cells had the 
propensity to develop into Th17 cells because infant CD4+ T cells express higher levels of 
Th17 related genes such as IL23R, RORγt and STAT3, than adults (19). These data suggest a 
developmental regulation of this CD4+ T cell subset, favoring Th17 development early in life.  
Regulatory T cells or Tregs are another subset of CD4+ T cells that are specialized in 
suppressive function to induce and attenuate immunological tolerance to self or non-self 
antigens (123, 124). This CD4+ Treg cell lineage can be divided into two populations, natural 
Tregs (nTregs), which arise during thymic development, and inducible Tregs (iTregs), which 
are derived from naïve CD4+ T cell circulating in the periphery and develop during the 
adaptive immune response.  The nTregs constitutively express the CD25 molecule, also 
known as IL2Rα chain, and the transcription factor, forkhead box P3 (FOXP3) (123, 125). 
These cells act to control self-reactive T cells in the periphery that have escaped thymic 
negative selection and thus, are responsible for self-tolerance, and hypo-responsiveness to 
tumor antigens. In contrast, iTregs suppress aberrant IL4 and IL13 responses, especially at 
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mucosal barriers (e.g. lungs), by restraining type-2 immune activation in the steady state 
(146). Inhibitory cytokines such as TGFβ and IL10 produced by Tregs have a role in 
modulating both protective and aberrant responses (34). Interestingly, neonatal T cells were 
found to have higher frequencies of natural regulatory T cells compared to adults. The 
numbers of FOXP3+ CD25high –expressing CD4+ T cells in infants increase rapidly in 
circulation during the first days of life (56), (160), (52), (87). Similarly, CD4+ CD25high Tregs 
were also found in higher frequency in fetal but not adult lymph nodes (LN) (93) . Tregs are 
already present at birth, have a memory phenotype, and express homing receptors than adults 
(52). Depletion of CD4+ CD25high Tregs increases T cell proliferation and IFNγ production of 
CD25neg CD4+ T cells (93). The presence of Tregs early in life likely has a role in controlling 
non-specific activation and establishing peripheral tolerance, but at the same time may also 
impede the generation of effective immunity.  
 Recently, another specialized subset of CD4+ T cells, Th9 cells, that produces the 
cytokine IL9, was defined. Though IL9 was described in the 1980s, recent research showed 
that Th9 cells mediate allergic inflammation, have protective roles in helminthes infection 
and autoimmunity. Such functions seemed to be distinct from Th1 and Th17-mediated 
immunity (51). PU.1, an ETS family transcription factor, has been identified as a key 
transcription factor in Th9 development. Th9 differentiation also required the cytokines 
TGFβ and IL4, as cells lacking the signaling components of these cytokines failed to express 
IL9 (62). Microarray analysis revealed that Th9 development required a transcriptional 
network that involved the expression of activator protein 1 (AP1) family transcription factor 
BATF (B-cell activating transcription factor-like) (61). Recent studies also revealed a role of 
the IL2-STAT5 axis in the differentiation of this new Th subset (82). Th9-IL9-producing 
	  	   12	  
cells have pleiotropic actions and affects a myriad of cells ranging from lymphocytes, mast 
cells, epithelial cells, smooth muscles and hematopoietic stems (51), (67). The role of Th9 in 
infant immunity is still elusive but it is possible that infants may preferentially develop this 
response as Th9 cells were discovered in the context of a Th2 response (86).  
 In addition to these Th subsets that can be found in blood and tissues, T follicular 
helper (Tfh) cells are found in lymphoid tissues. They have an important role in inducing 
antibody production by B cells and in the generation of long-lived high affinity plasma and 
memory B cells (84). Tfh develop when naïve CD4+ T cells receive signals through their 
TCR, co-stimulatory signals, and when the co-polarizing cytokines IL6 and IL21 induce c-
maf and up-regulate the transcriptional repressor Bcl-6 (84). Tfh cells express CXCR5, 
which allow their migration towards the B cell follicle, and ICOS on their cell surface (32), 
(84). Moreover, they have a distinctive transcriptional profile that reflects their role as 
professional B cell helpers where they ensure that only germinal center (GC) B cells with the 
highest affinity for the specific Ag will survive, differentiate and become long-lived plasma 
cells (84). It has been implied that in persistent infections, CD4+ T cell differentiation could 
be redirected towards the generation of CD4+ Tfh to ensure continued humoral immune 
responses (44). Though limited data are available about CD4+ Tfh in human infants, recent 
studies in newborn mice demonstrated that both the neonatal environment and T cell-intrinsic 
factors influenced the development of Tfh responses and the use of adjuvants in 
immunization could result in adult like GC responses (92). Tfh cells seemed to develop in 
vaccinated newborn mice but were impaired in function and had defective localization in 
GCs (36). The frequency of these cells and the mRNA of their associated transcription factor, 
Bcl-6 and cytokine IL21 were decreased and was associated with defective antibody 
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responses. Interestingly, IL4, a Th2 associated cytokine seemed to modulate the function of 
Tfh cells by promoting their development, emergence, localization to and formation of GCs 
(36). These findings suggest an important role of Tfh in antibody development and may have 
implications in the reduced antibody responses observed in infants.   
 The development of the distinct CD4+ T cell lineages discussed depends on the 
complex interplay of cytokine networks. The next section will describe in more detail the 
role of cytokine signaling in the generation of effector CD4+ T cells, especially regarding the 
Th1 and Th2 fates.  
Cytokine signaling contributes to effector CD4+ T cell generation 
 
CD4+ T cell differentiation is a dynamic process. The acquisition of the unique and 
plastic fates of effector CD4+ T cells requires the activation of a complex cytokine and 
transcription factor network. During antigen encounter, the cytokine milieu is essential in 
determining the fate of a naïve CD4+ T cell and the generation of an adaptive immune 
response. Infants have been demonstrated to be inefficient in producing certain effector 
cytokines, particularly, IFNγ, the major product of Th1 cells. The reduced production of this 
cytokine is associated with the infant’s susceptibility to intracellular pathogens. Thus, it is 
necessary to understand whether cytokine-mediated signaling in infant CD4+ T cells differ 
from adults and whether such mechanism can explain the unique immune status of infants.  
Understanding the role of cytokine signaling in the generation of protective immunity will 
likely provide additional parameters to put in consideration when implementing better 
interventions that are effective in the pediatric populations. 
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Cytokine levels in the periphery can be used to indirectly assess cellular immunity as 
they serve as effector proteins of immune cells, particularly CD4+ T cells. Analysis of IFNγ 
and IL4 concentration in normal sera showed that IL4 was produced earlier than IFNγ in CB, 
at day 1 and day 5 after birth (118). Stimulation with non-specific stimulants or mitogens 
(Staphylococcal enterotoxin B (SEB), lipopolysaccharide (LPS) or phorbol 12-myristate 12-
acetate and ionomycin (P/I) revealed that the cytokine-producing capacity in infants 
increased from birth to 1 year of age but remained weaker compared to their mothers or other 
adults (76). Early comparative studies in neonates, older children and adults demonstrated 
that the Th1-cytokine-producing capability increased with age and was correlated with 
expression of CD45RO, suggesting antigen exposure dependency (58). Th2 cytokine 
production was minimal across all age groups (31). Additionally, when purified CD4+ T cell 
populations were used (CD4+ CD45RA+ T cells or CD4+ CD45RO+) and stimulated by 
polyclonal activation, adult, but not CB purified cells secreted the cytokines IFNγ, IL2, and 
IL4 and seem to be impacted by the environment (30), (41), (54). Some of the CD4+ T cell 
data appeared contradictory and difficult to interpret because the various studies employed 
different conditions to measure Th1 or Th2 associated cytokines in the infant. Therefore, they 
might not necessarily depict an accurate picture of the infants’ potential to secrete and, 
equally important, respond to these effector cytokines. Determining which signaling 
components are differentially activated in infant compared to adult CD4+ T cell will be 
critical in identifying factors leading to distinct IFNγ and IL4 production in infants and their 
skewed differentiation to CD4+ Th2 cells.  
Cytokines regulate cellular responses by long-term transcription-dependent or short-
term transcription-independent mechanisms (18). The former, which represents the 
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traditional signaling route, is primarily the JAK/STAT signal transduction pathway. 
Cytokines activate specific Janus kinases (JAKs) and signal transducer and activator of 
transcription (STAT) molecules to affect gene transcription or repression (Figure 1). Given 
that the JAK/STAT signaling pathway can affect a wide range of immune responses ranging 
from immune defense, differentiation, proliferation and even oncogenesis, this pathway is 
strictly regulated. Regulation is achieved through numerous levels including receptor 
expression, kinase activation, cytoplasmic transcription phosphorylation and negative 
regulator expression. Its relevance is highlighted by the ability of viruses to escape the 
immune system by inactivating the different components of the JAK/STAT pathway (70).  
For cells to be receptive to cytokines, they must possess the necessary receptors on 
the cell surface. IL4 binds to type I receptors which are characterized by the presence of 4 
conserved cysteine residues Trp-Ser-X-Trp-Ser, the WSXWS sequence motif, and the 
fibronectin type II modules in the extracellular domain, whereas IFNγ utilizes Type II 
receptors (R1 and R2) without the WSXWS sequence motif, and have tandem fibronectin 
type III domains (77), (73). The IL4 receptor complex is composed of the IL4Rα/IL13Rα1 
and γc (common gamma chain), while the IFNγ receptor complex consists of 2 chains, the 
p90 binding chain, IFNγR1 and p35, the accessory signal transducing chain or IFNγR2 (78), 
(77), (122). Receptor density and ligand affinity can modulate the effects of cytokines. For 
example, IFNγR2 expression in human T cells is higher in the cytoplasm compared to the 
cell surface, possibly suggesting intracellular trafficking of receptors to control the effects of 
its ligand (122). IL4 receptor expression on human T cells can be affected by various 
signaling pathways, and by IL4 itself at both the transcriptional and posttranscriptional level 
(40). In tissues, IL4 is secreted by Th2 cells, Tfh cells and basophils, but there are potential 
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other sources such as mast cells, eosinophils, NK T cells and innate lymphoid cells 2 (ILC2) 
(146). In response to infection, innate immune cells such as natural killer (NK) and natural 
killer T (NKT) cells are the first source of IFNγ. During the adaptive phase when antigen-
specific T cells are generated, both CD4+ and CD8+ T cells gain the ability to produce IFNγ. 
However, naïve CD8+ T cells by default, are programmed to be IFNγ-producing cytotoxic T 
cells while CD4+ T cells differentiate into different lineages where only Th1 cells produce 
substantial amounts of IFNγ (128). 
 
  
Figure 1: Schematic of cytokine signaling in a CD4+ T cell. A. Cytokines such as IFNγ or 
IL4 will bind to their respective receptors. Receptor- associated JAKs are phosphorylated (B) 
and activate STATs (C) which then dimerize and translocate to the nucleus (D), where they 
activate or suppress genes and thereby determine the production of effector molecules, e.g. 
cytokines (E). 
 
 
In a non-activated state, cytokine receptors exist as individual subunits in the plasma 
membrane and lack kinase activity (18). When cytokine-binding to its receptor is initiated, 
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downstream molecules are activated to relay the signal to the cell’s nucleus to affect gene 
expression. This signal is communicated inside the cell through receptor dimerization and 
phosphorylation of tyrosine residues on the cytoplasmic tail of receptors by JAKs, which 
serve as docking sites for the SH-2 domain of STATs, which themselves are phosphorylated 
by JAKs, allowing STAT molecules to homo- or heterodimerize and translocate to the 
nucleus to activate or suppress gene transcription (133), (103, 111), (105), (108).  
The Janus kinase family is composed of 4 members: JAK1, JAK2, JAK3 and TYK2 
(tyrosine kinase 2) (133). The receptors undergo conformational changes, which permit their 
associated JAKs to trans-phosphorylate each other, and by phosphorylating conserved 
tyrosine residues in the cytoplasmic tail of their coupled receptors. JAK 1 is involved in the 
signaling of the IL4-receptor family (IL4R, IL13R) whereas both JAK1 and JAK2 are 
associated with the IFNγ receptor complex. These kinases have been shown to be essential 
for host immunity as knockout of these components results in embryonic and perinatal 
lethality, or at a minimum hypersensitivity to infectious pathogens (133). Moreover, 
enhanced expression of JAKs and related receptors in effector CD4+ T cells associated with 
chronic inflammatory diseases like multiple sclerosis underlines their significance (33).  
There are 7 mammalian STATs (STAT1, 2, 3 4, 5a, 5b, & 6) described to date and 
their actions involve binding to response elements associated with the promoter of their 
target genes and modulating transcription through recruitment of transcriptional co-activators 
or repressors (108), (111), (127). STAT1 was discovered to mediate IFNγ signaling to target 
genes that promote inflammation and antagonize proliferation, whereas STAT6 transduces 
signals from IL4 to polarize naïve CD4+ T cells into Th2 effectors and promote B cell 
function by binding to IgE promoter on B cells or IL4 promoter on T cells (127), (95), (58). 
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Mutations in STAT1 are associated with susceptibility to viral and mycobacterial infections 
while STAT4 variant alleles are involved in the pathophysiology of systemic lupus 
erythematosus (SLE), an autoimmune disease (104).  
The onset of JAK/STAT signaling is rapid and so is their termination. The 
termination or decay in signal involves down regulation of receptors, JAKs and STATs. 
STATs are dephosphorylated by phosphatases and are inactivated by suppressor of cytokine 
signaling (SOCS) proteins (127). There are 8 members within the SOCS family, and they are 
SOCS1 through SOCS7 and CIS (75). SOCS 1, 2 3 and CIS are present in cells at low or 
undetectable levels but are rapidly induced by cytokines such as IL4, IFNγ, IL2, IL3, IL6 and 
others (75). Moreover, SOCS 1 and 3 can inhibit signaling by IL4 and IFNγ. Indeed, research 
in the field has demonstrated that SOCS proteins regulate the differentiation of CD4+ T cells 
into Th1 or Th2 lineage. (42). Thus, tight regulation of cytokine signaling via JAK/STAT is 
vital, as excessive stimulation will result in tissue damage. 
Considering that IFNγ and IL4 cytokines have diverse effector roles in the immune 
system, different transcriptional programs must be activated by these cytokines. Complex 
populations such as peripheral blood mononuclear cells (PBMCs) will most likely activate or 
express a different transcriptional program than purified populations. The transcriptional 
response of PBMC to IFNγ was shown to be restricted to a subset of type I interferon-
inducible genes and the amplitude of the response increased with IFNγ dose (150). 
Comprehensive profiling of genes specifically expressed by human activated Th1 and Th2 
cells have offered insights into the molecular basis of Th1/Th2 development and especially in 
human diseases in which these 2 subsets are involved (98). CD4+ T cells from CB showed 
reduced expression of NFATc2  (nuclear factor of activated T cells c2), a critical 
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transcription factor necessary for the up-regulation of multiple cytokines known that can 
amplify T cell allogeneic responses, and also regulate IFNγ, and IL4 cytokine responses (65). 
In contrast, in graft-versus-host disease, cytokine gene array and RNAse protection assay 
revealed that Th2 responses in CB were lower compared to adults due to the reduced mRNA 
expression of c-maf, an important transcription factor regulating Th2 cytokine expression 
(65). Independent of the study setting, gene transcription in infants and adults significantly 
differed. Equally important, the components of the JAK/STAT signaling pathway are 
undeniably pivotal in determining how cytokines influence cellular processes such as T 
helper differentiation. Epigenetic studies had also shown that naïve T cells that have been 
stimulated by antigens seemed to show low, nonselective transcription of Ifng and the Th2 
cytokine cluster (Il4 locus) (8). Moreover, differentiations of certain lineage rely on 
additional signals such as cytokines, that induce differentiation, as the genes are poised in the 
chromatin context to be either epigenetically activated or silenced (8) There seemed to be 
regulatory mechanisms in place to control both the production and the response to cytokines. 
In the unique infant environment, how tolerance and T cell responses against pathogens are 
balanced are not well understood. Clearly, an intricate crosstalk between multiple 
immunological processes including signaling and epigenetic changes will influence the 
generation of CD4+ T cell immunity.  
Role of CD4+ T cells in Antiviral Immunity 
  
 The importance of CD4+ T cell immunity is highlighted in their ability to influence 
the function of other lymphocytes. In the context of viral infections, infants compared to 
adults have increased susceptibility to viral infections such as HCMV, HIV, and Hepatitis B 
virus (HBV) resulting in high morbidity and mortality worldwide (115), (116). The viral 
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burden imposed by these viruses illustrates that infants have an altered CD4+ T cell response 
that are inefficient in controlling these pathogens. Similarly, infant responses to vaccination 
are generally weaker compared to adults supporting the need for better ways to optimize 
infant vaccination strategies. This section will discuss the current understanding of CD4+ T 
cell immunity in the context of HCMV infection as substantial aspect of my graduate work 
was focused on modeling CMV infection in infant rhesus macaques.  
 HCMV infection in utero is the most prevalent congenital infection, afflicting 
newborns in the developed world. Recent data estimated that congenital CMV infection 
occurs in up to 6.2% of live births following primary infection, re-infection or maternal 
HCMV reactivation (116). CMV-infected newborns suffer severe disease and may develop 
neurodevelopmental sequelae, particularly sensori-neural deafness (116). Interestingly, 
perinatal acquisition of CMV, most likely via breast milk (BM) by healthy infants, is 
asymptomatic and their viral load is not as high as in congenitally infected infants. However, 
these HCMV infected infants and children who acquire HCMV from contaminated saliva 
have prolonged viral shedding compared to adults with primary HCMV infection (5).  
In contrast to robust and comparable CMV-specific CD8+ T cell responses to adults, 
CMV-specific CD4+ T cell responses in infants are persistently deficient. Specifically, IFNγ 
production by these CMV-specific CD4+ T cells was highly reduced in children even after a 
year since acquiring CMV (143). Concomitant with diminished IFNγ production, IL2 
production and expression of the co-stimulatory molecule, CD40-ligand, were also reduced. 
More recent CMV studies also reported that CMV-specific CD4+ T cell responses were very 
low in children under 2 years of age but become detectable with increasing age (83). Taken 
together, these data suggest that failure to control CMV in the young is associated with the 
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age-dependent development of CD4+ T cell immunity. The molecular mechanisms 
underlying this differential antiviral response of infant and adult CD4+ T cells are still not 
clear.  
The thesis work describe here investigates immune ontogeny, maturation and 
cytokine signaling. In Chapter 2, we took advantage of the non-human primates (NHPs), 
rhesus macaques (Macaca mulatta), to identify age-related differences in immune system 
development in infants, juveniles and adults in the context of a viral infection. We compared 
2 groups of animals that were raised to be specific pathogens free (SPF) and naturally 
infected with RhCMV. We explored whether age and viral burden affect frequency and 
function of immune cells. Chapter 3 describes SPF infants and adults that were 
experimentally infected with RhCMV. We determined the shedding of RhCMV in bodily 
fluids to evaluate the development of adaptive immunity in the infant and adult animals. 
Chapter 4 describes our work done using human samples. We described the differences in 
cytokine signaling in CD4+ T cells as an effort to reveal a molecular mechanism that might 
play a role in the unique function of infant CD4+ T cells. A deeper understanding of immune 
development should help in elucidating what molecular mechanisms are influencing CD4+ T 
cell immunity in infants. 	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CHAPTER 2: THE INTERPLAY BETWEEN IMMUNE MATURATION, AGE, 
CHRONIC VIRAL INFECTION AND ENVIRONMENT 	  
OVERVIEW 	  
Maturation and age are dynamic processes. Associated with people living longer, 
numerous health ailments are increasing from cardiovascular diseases to cancer suggesting 
dysregulation in immune function with age or immunosenescence. One possible reason that 
leads to immunosenescence is exposure to a lifetime inflammatory environment caused by 
both clinical and subclinical infections described as “inflammaging”. Determining T cell 
development, maturation, and function from birth to adulthood are important parameters to 
assess changes in cellular immunity with age and the impact of a lifelong viral infection. In 
this study, we use rhesus macaques of specific (SPF) and non-specific pathogen free (non-
SPF) status to characterize basic immunological changes in peripheral blood cell populations 
with age and how they are affected by chronic cytomegalovirus infection (RhCMV). Our 
findings indicated that age-related changes in major blood cell populations from birth to 
adulthood are common to both SPF and non-SPF macaques.  We also demonstrated that 
chronic RhCMV infection modulates immune development over the lifetime of the host, 
evident in juvenile RhCMV-infected macaques. These altered immune responses in non-SPF 
animals may predispose them for inflammaging in late adulthood. These data support the 
idea that rhesus macaques could serve as a model system to study inflammaging and the 
possible factors leading to immunosenescence. 
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INTRODUCTION  
Immune development and aging are dynamic processes that are governed by many 
distinct, yet interacting factors. Lifespans are mostly increasing worldwide, yet there have 
been concomitant increases in age-related morbidities, particularly cardiovascular diseases, 
increased susceptibility to seasonal infection, cancers, and neurodegenerative disorders.  A 
unifying link between the increased disease rates from these disparate diseases observed in 
aging populations is the progressive decline in immune functions brought on by both intrinsic 
and extrinsic factors.  This phenomenon has been termed “immunosenescence”, and the 
etiologies of immunosenescence are incompletely defined. A central driving force in decline 
in immune function is the inherent process of progressive thymic involution, which results in 
an extremely restricted generation of naïve T cells by the fifth or sixth decades of life.  
However, studies over the past several years have emphasized the critical importance of 
extrinsic factors, which when layered over thymic involution, can produce a “conspiracy of 
immune dysfunction” that can increase rates of morbidity and mortality in aging individuals. 
Several hypotheses have been presented to explain the mechanistic basis for increased 
disease susceptibility associated with aging. Many of these focuses on the age-related 
development of pro-inflammatory state that is observed in many aging individuals, a process 
that have been termed “inflammaging”. Multiple studies have demonstrated increased 
production of inflammatory cytokines with age, and the causes for inflammaging are likely 
multifactorial and remain to be determined (94), (16). Several polymorphisms in genes for 
IL6, IL10, and TLR4 have been associated with increased inflammation during aging (9), 
(10), (22), (46), (47), (60), (45). Interestingly, this association was more pronounced in men 
than in women suggesting that hormones may influence the aging process. In fact, a recent 
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review discussed principle age-related alterations of the endocrine system that could 
influence immunity (60). 
An alternative theory points to chronic infections as major driver in 
immunosenescence, and, in fact, the processes of immunosenescence and inflammaging may 
be inextricably intertwined. Among the various known chronic viral pathogens, human 
cytomegalovirus (HCMV) in particular, has been suggested to be associated with reduced 
immune function in older individuals (68), (141), (23), (48). HCMV is ubiquitous throughout 
the world with adult seroprevalence rates of 50-100%.  HCMV, a member of Herpesvirales 
order of viruses, is considered to be a virus with low pathogenic potential in immune 
competent hosts, but like all Herpesvirales members, it establishes a lifelong persistence 
within the infected individual.  Persistence is characterized by the presence of cells harboring 
latent HCMV genomes that periodically and asymptomatically reactivate to produce progeny 
virions that can be secreted in bodily fluids.  Although HCMV has low pathogenic potential 
in an immune competent host, evidence indicates that the virus-host relationship is unlike 
that for any other virus, and this relationship has important clinical implications in relation to 
immunosenescence. The implications stem from persistent antigenic stimulation of the 
immune host, resulting in an extraordinarily large devotion of the infected host’s immune 
repertoire to HCMV. 
A seminal study by Sylwester et al quantified the CD4 and CD8 T cell responses to 
the HCMV proteome in 32 healthy long-term HCMV-infected individuals (138). On average, 
almost 10% of memory CD4 and CD8 T cells are specific to HCMV antigens, far exceeding 
in magnitude the frequency of antigen-specific T cells to any other pathogen. Other studies 
have indicated that there are progressive oligoclonal expansions of some of the HCMV-
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specific T cell populations.  The majority of HCMV-specific effector memory cells are 
terminally differentiated, considered to be dysfunctional and thereby, immunosenescent.  
Furthermore, the hypothesis has been presented that the vast expansion of HCMV-specific T 
cells consumes the available finite “niche” for immune cells and interferes with the 
development of effector and memory cells targeting other pathogens (48). At the same time, 
the persistence of antigens continuously induce stress signals promoting inflammation (48). 
Although seminal studies like the OCTA, NONA and NHANES cohort studies have shown a 
statistical association between aging, reduced immune function, increased C-reactive protein 
(CRP) levels and HCMV seroprevalence, cause and effect cannot be conclusively 
distinguished (156), (157), (7), (140).  
The underlying mechanisms of and associations between chronic infections and 
immune function could be best determined and tested in an animal model that closely 
recapitulates characteristics of human development, physiology, immunology, virology, and 
longevity. We propose that rhesus macaques represent such a model.  Wild and captive 
populations of rhesus macaques are ubiquitously infected with rhesus cytomegalovirus 
(RhCMV), as well as other persistent pathogens.  Furthermore, RhCMV-infected monkeys 
show similar age-associated immune changes as those observed in HCMV-infected humans 
have been noted in these, including decreased CD4+ to CD8+ T cell ratios and the 
accumulation of terminally differentiated CD8+CD28- T cells (63), (112), (100).  In captivity, 
these animals live for an average of 25 years and a maximum of approximately 40 years. 
Although their lifespan is shorter compared to humans, macaques undergo similar 
developmental, hormonal and immunological changes, but in an accelerated fashion 
compared to humans. 
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The current study characterizes basic immunological parameters in peripheral blood 
cell populations in relation to 1) age, 2) housing environment and 3) the presence or absence 
of a persistent virus (RhCMV). Taking advantage of the unique resource of rhesus macaques 
that were bred and raised be Specific Pathogen Free (SPF), for specific viruses (described 
below), we compared the immune development of SPF infant macaques from birth 
throughout their first year to non-SPF infant macaques that were raised in a similar nursery 
environment.  Once the animals were transferred to outdoor corrals at one year of age, we 
asked whether the SPF status of an animal would affect immune modulation induced by 
pathogenic or other stimuli.  Specifically, we investigated how immune responses to RhCMV 
evolve over the lifetime of a chronically infected animal in correlation with virological 
parameters, and whether immune cell populations of RhCMV-infected animals would 
display distinct functional characteristics compared to SPF animals without RhCMV 
infection of the same age. 
Our results show that age-related changes in major blood cell populations from birth 
to adulthood are common to both SPF and non-SPF macaques.  In addition though, our study 
clearly demonstrates that chronic RhCMV infection modulates immune development over 
the lifetime of the host. These altered responses were already evident in juvenile RhCMV-
infected macaques, thereby potentially predisposing these non-SPF animals for inflammaging 
in late adulthood. These data support the idea that rhesus macaques could serve as a model 
system to study inflammaging, and provide a foundation for future studies to delineate 
specific mechanisms of RhCMV-induced immunosenescence with the long-term goal of 
developing therapeutic interventions, targeted to young adults, to prevent the onset of 
inflammaging. 
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MATERIALS AND METHODS  
Animals  
Genetically outbred infant rhesus macaques (Macaca mulatta) of Indian (n=13; 8 
male and 5 female infants) or Chinese (n=10; 8 female and 2 male infants) origin were 
obtained from the specific pathogen-free (SPF) colony at the California National Primate 
Center (CNPRC). SPF status was defined as being seronegative for simian type D retrovirus 
(SRV), simian immunodeficiency virus (SIV), simian T cell lymphotropic/leukemia virus 
(STLV), Cercopithecine herpesvirus 1 (CHV-1; herpes B virus), RhCMV, simian foamy 
virus (SFV), and rhesus rhadinovirus (RRV). In addition, 11 non-SPF infant macaques from 
the conventional colony were included for comparison. SPF and non-SPF infant macaques 
were removed from their dams at birth and nursery-reared indoors. After 9 months to 1 year, 
they were relocated to outdoor SPF or non-SPF animal corrals, respectively. SPF juvenile 
macaques (n=28; 3-5 years), and non-SPF juvenile (n=50; 3-5 years) or adult macaques (SPF 
n=8, 12-12yrs) and non-SPF adults (n=98, 12-20 years) macaques were of Indian origin and 
housed outdoors (Table 1). Representative of the CNPRC colony’s effort to increase 
breeding age female macaques, the gender distribution was shifted toward female macaques 
that represented 65% of SPF juveniles, 42% of non-SPF juveniles, and 70.5% of adult non-
SPF macaques.  The Institutional Animal Care and Use Committee of the University of 
California, Davis (UC Davis), which is fully accredited by the Association for Assessment 
and Accreditation of Laboratory Animal Care, approved all animal protocols in advance of 
any procedures.  
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Sample collection and processing 
Animals were immobilized with (10mg/kg) ketamine-HCl intramuscularly (IM) prior 
to all sample collections. Complete blood counts (CBC) were performed at each blood 
collection. Infant EDTA blood samples were collected longitudinally starting at birth and 
subsequently every month for one year.  Plasma was removed from whole blood by 
centrifugation and stored at -80°C for antibody measurement. Peripheral blood mononuclear 
cells (PBMCs) were isolated from whole blood via density centrifugation using lymphocyte 
separation medium (LSM) (MP Biomedicals, Solon, OH) or Accu-Paque Lymphocyte 
(Accurate Chemical & Scientific Corp., Westbury, NY) density gradient as described (91), 
(1), (2). Due to the low blood volume, and therefore relatively low cell counts, infant PBMCs 
were immediately used for functional analyses. PBMCs from juvenile and adult macaques 
were cryopreserved and batch-analyzed.  
Complete blood count (CBC) 
EDTA blood samples were analyzed on a HORIBA Pentra 60+ electronic cell counter 
(HORIBA Diagnostics, Irvine, CA). A standard blood smear was prepared from the EDTA 
sample and stained with a Wright-Giemsa stain (Harleco, EM Scientific, Gibbstown, NJ).  
Manual 100-cell differentials were performed for the differentiation of white blood cells.  
The relative percentage of each cell type was obtained and then multiplied by the total white 
blood cell count to get the absolute numbers of each cell population.   
T cell stimulation 
 Infant PBMCs were resuspended with RPMI 1640 media (Cellgro, Manassas, VA) 
supplemented with 10% heat-inactivated FBS (Cellgro, Manassas, VA) and L-glutamine-
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penicillin-streptomycin antibiotic cocktail (Sigma, St Louis MO) at 1.0 x106 cells/ml.  
Negative controls were cultured in media only.  To evaluate polyclonal T cell responses, 
PBMC were stimulated with phorbol 12-myristate 12-acetate (PMA) at 10ng/ml and 
Ionomycin (I) at 125ng/ml (Sigma). The cells were incubated for a total of 12 hours at 37°C 
and 5% CO2 with Brefeldin A (3.0µg/ml) being added after the first hour (eBioscience, San 
Diego, CA).  At the end of the culture period, cells were stained for surface antibodies, fixed, 
and permeabilized for intracellular cytokine staining (see below) as described previously (91), 
(1), (2). 
In addition, infant PBMCs were stimulated through the TCR with anti-CD3 and anti-
CD28 antibodies. Microtiter tissue culture plates were coated overnight with 10µg/ml of pure 
CD3 (SP34-2) and 10µg/ml pure CD28 (L293) in 100 µl of PBS/ well.  The next day, plates 
were washed 3x with PBS.  Cells at 1x106 /ml were then aliquoted at 100 µl/well and 
cultured for 24 hours at 37°C and 5% CO2.  Supernatants were collected and stored at -800C 
until analysis using the Milliplex MAP Nonhuman Primate Cytokine Panel (EMD Millipore, 
Billerica, MA). 
Similarly, 1.25 x 106 PBMCs/ml from juvenile and adult macaques were resuspended 
in RPMI with 10% FBS and stimulated with 25µg/ml concanavalin A (Con A) or 25µg/ml 
RhCMV lysate prepared from an infected cell extract exhibiting 100% cytopathic effect.  
Negative control cultures consisted of cells in media only. Cell culture supernatants were 
collected after 48 hours and were immediately analyzed in duplicates for multiple soluble 
markers using multiplex bead arrays (Bioplex Suspension Array System with Bioplex 
Manager 4.0 software by Bio-Rad Laboratories, Hercules, CA, or Milliplex MAP Nonhuman 
Primate Cytokine Panel by EMD Millipore).   
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Flow cytometric analysis:  
T cell or B cell subpopulations were analyzed for activation or memory cell 
differentiation using standard surface staining protocols (91), (1), (2). The ability of the CD4+ 
and CD8+ T cells to produce cytokines in response to PMA/ Ionomycin stimulation was 
evaluated using the following logical gating strategy: PBMC gate (FSC-A vs. SSC-A), 
singlets (FSC-H vs. FSC-A), T cells (CD3+CD4+ or CD3+CD4- = CD8+ T), followed by 
gating for IFNγ, IL2 and/or TNFα within the CD4+ or CD8+ T cell populations. Samples were 
acquired on a FACS Aria flow cytometer (BD Biosciences).  A minimum of 300,000 events 
were acquired for T cell stimulation responses and 30,000 events for phenotyping studies.  
Data were analyzed using FlowJo Software (Tree Star, Ashland, Oregon) and Boolean gating 
strategies were applied when appropriate. Cytokine CD4+ or CD8+ T cell responses were 
considered positive if their frequencies were at least 2 times higher than in unstimulated 
(media) PBMCs and if their actual value was ≥0.01%. Data are reported as percentage of 
CD4+ or CD8+ T cells. 
Juvenile and adult whole blood samples were stained with direct labeling of whole 
blood with antibodies for CD3, CD4, CD8, CD20, CD25, CD28, CD45RA, CD95, HLA-DR, 
CD195 (CCR5) (BD Biosciences, San Jose, CA), and CD38 (Nonhuman Primate Reagent 
Resource or StemCell Technologies). Whole blood samples were divided, stained with 
antibody cocktails to analyze T cell maturation and activation, washed, red cells were lysed, 
and then PBMC were fixed using a Coulter TQ Prep System (Coulter Corporation, Hialeah, 
FL). Samples were acquired on a FACS Calibur and analyzed with CellQuest software (BD 
Biosciences, San Jose, CA) 
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RhCMV antibody measurement  
RhCMV-specific binding antibodies were determined by ELISA as previously 
described (85), (163). Briefly, 96-well Immulon 4HBX plates (Fisher-Thermo) were coated 
overnight at 4°C with whole RhCMV lysate (0.5mg/ml) Plasma samples were diluted at 
1:100. Anti-Rhesus IgG peroxidase-conjugated antibody was used to detect anti-RhCMV 
IgG (KPL, Gaithersburg, Md.). The specificity and reproducibility of the ELISA was 
confirmed using animal sera that were previously confirmed to be RhCMV positive and a 
plasma pool of seronegative animals. The limit of detection (LOD) was based on the average 
OD values plus 0.1 OD obtained for the plasma pool of RhCMV negative animals at the 
lowest dilution of 1:50. Antibody titers are reported as the lowest plasma dilution at which 
OD values were above the OD value for the RhCMV-negative plasma pool. RhCMV 
neutralizing antibodies (nAb) were determined as described previously (Abel, 2008, 2011). 
Data are reported as the reciprocal of the dilution that resulted in 50% neutralization (NT50). 
RhCMV quantitation 
Oral saliva swabs were collected from both RhCMV-seropositive non-SPF juveniles 
and adults. RhCMV was quantitated as previously described (59), (131). Real-time PCR for 
RhCMV gB was performed using the following primer and probe pair: forward primer: 5’-
TGC GTA CTA TGG AAG AGA CAA TGC-3’, reverse primer: 5’-ACA TCT GGC CGT 
TCA AAA AAA C-3’ (Invitrogen, Carlsbad, CA), and probe (5’-3’) TET-CCA GAA GTT 
GCG CAT CCG CTT GT-TAMRA (Applied Biosystems, Carlsbad, CA). RhCMV was 
quantitated based on a RhCMV gB plasmid standard curve spanning 10^0 to 10^6 copies. The 
viral load was calculated as RhCMV gB copies per ml for saliva. The limit of detection was 
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10 copies of RhCMV gB.  
Statistical analysis 
The data are presented as median values if not indicated otherwise. Results between 
two or more groups were compared by Student’s t-test or one-way ANOVA, respectively, 
using GraphPad Prism, version 5 (GraphPad, Inc., La Jolla, CA).  Nonparametric Mann-
Whitney tests or Kruskal-Wallis tests with Dunn’s Multiple Comparisons were applied when 
we observed large variation within a group, which is not untypical due to the outbred nature 
of rhesus macaques. An exact Wilcoxon signed-rank test was used to test the null hypothesis 
that in vitro cytokine responses to PMA/ Ionomycin stimulation in 40 to 48 week old infants 
are not different from responses in infants between 0 to 4 weeks of age. To perform this 
statistical analysis, absolute numbers of cytokine producing CD4+ or CD8+ T cells per 1 
million CD4+ or CD8+ T cells were used instead of percentages. An estimate of location shift 
and corresponding 95% confidence interval were also computed. Adjustments for multiple 
testing were not applied due to the exploratory nature of the study and the relatively small 
sample sizes. 
RESULTS 
 
Infant immune development in a nursery setting 
SPF infant macaques were reared in an indoor nursery in small groups of 2-3 animals 
per cage. Infants born to non-SPF dams were housed under identical conditions but in a 
separate room of the nursery.  Therefore, both infant groups were housed in a similar 
environment with minimal pathogen exposure, received identical food, and had no contact 
with older animals that could potentially harbor transmittable pathogens.  These controlled 
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conditions allowed us to define general immune changes in infant peripheral blood cell 
populations after birth.  Furthermore, by including equivalent numbers of SPF Indian and 
SPF Chinese infant macaques, we could determine whether the genetic origin of the animals 
influenced early immune development. Non-SPF macaques were of Indian origin only. 
The longitudinal analysis of major blood cell populations in SPF infants revealed 
population-specific patterns of developmental changes during the first year of life (Figure 1; 
Table 1). Neutrophils constituted the most abundant cells at birth, but rapidly declined during 
the first 12 weeks. Monocytes showed a similar decline. In contrast, lymphocyte numbers 
increased steadily. At birth, the vast majority of lymphocytes represented T cells; B cell 
numbers were relatively low (Figure 2). Both T and B lymphocyte numbers increased after 
birth, but the increase in absolute B cell numbers was much more pronounced (Figure 2A-D).  
On average, B cell numbers increased more than 5 times, while T cell numbers less than 
doubled.  Between the two main T cell subsets, CD4+ T cells outnumbered CD8+ T cells at 
birth with CD4:CD8 T cell ratios ranging from 2.5 – 8.8 (Figure 2E).  After birth, the CD8+ T 
cell population showed a marked expansion (1.0 to 8.8-fold increase), whereas CD4+ T cell 
numbers only slightly increased (0.8-3.0 fold increase) from birth to 3 months of age. As a 
result, the CD4:CD8 T cell ratio declined (Figure 2E), eventually stabilizing at a 2:1 ratio of 
CD4:CD8 T cells, which is typical for juvenile and adult macaques (Table 2).  The expansion 
of T cells occurred concurrently with rising Ki67+ CD4+ and Ki67+CD8+ T cells during the 
first weeks after birth (Figure 2F).  Consistent with the larger increase in CD8+ T cell 
numbers, the percentage of Ki67+ T cells was higher in the CD8+ than the CD4+ T cell 
population. Thus, during the first few months of life, the various blood cell populations 
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changed significantly in their absolute frequencies and their relative proportions to each other 
(Tables 1 and 2), reaching steady state levels between 12-24 weeks of age (Figures 1 and 2).  
Neutrophils
0 4 8 12 16 20 24 28 32 36 40 44 48 52
0
2000
4000
6000
8000
10000
Age (weeks) 
N
e
u
tr
o
p
h
ils
±
S
E
M
/ µ
l o
f B
lo
o
d
Monocytes
0 4 8 12 16 20 24 28 32 36 40 44 48 52
0
100
200
300
400
500
600
700
800
Age (weeks) 
M
o
n
o
cy
te
s±
S
E
M
/ µ
l o
f B
lo
o
d
Lymphocytes
0 4 8 12 16 20 24 28 32 36 40 44 48 52
0
2000
4000
6000
8000
10000
SPF Infant
Non-SPF Infants
Age (weeks) 
L
ym
p
h
o
cy
te
s±
S
E
M
/ µ
l o
f B
lo
o
d
 
Figure 1: Longitudinal changes in major blood population during the first year of life. 
The graphs show longitudinal changes in the frequencies of absolute neutrophils (left panel), 
monocytes (middle panel), or lymphocyte numbers (right panel) in peripheral blood of SPF 
(open circles) and non-SPF (closed circles) infant macaques from birth to 1 year. Data are 
represented as mean absolute numbers ± SEM per microliter of blood. A total of 23 SPF 
infants were included and 11 non-SPF infants were followed until week 16, but only 4 non-
SPF macaques were followed until week 52. 
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Table 1: Peripheral Blood Mononuclear Cell Populations 
Cell Population Median Cell Numbers/ µ l Blood (Minimum-Maximum No.) 
 Infants (40weeks) 
Juveniles 
(3-5yrs) 
Infants vs. 
Juveniles 
Adults 
(>12yrs) 
 
Juveniles vs. 
Adults 
SPF                                 n=23                             n=20                                                   n=8 
Lymphocytes 4608 (2596-7314) 
1949 
(1107- 3088) <0.0001 
710 
(342-2388) p=0.0014 
Monocytes 182 (45-637) 
328 
(229-855) <0.0001 
938 
(476-2030) <0.0001 
Neutrophils 1952 (990-4900) 
10502 
(6897-15355) <0.0001 
11274 
(10032-19694) NS 
Non-SPF                        n=11                             n=50                                                    n=98 
Lymphocytes 2874 (2016-5838) 
3037 
(756-8073) NS 
1248 
(262-3888) <0.0001 
Monocytes 534 (261-990) 
266 
(0-1620) NS 
291 
(0-1494) NS 
Neutrophils 6764 (4026-12525) 
9576 
(1936-21156) NS 
8280 
(2520-20169) 0.0119 
Comparison of SPF versus Non-SPF Populations 
Lymphocytes NS p<0.0001 (SPF<non-SPF)  NS  
Monocytes NS NS  p=0.0002 (SPF>non-SPF)  
Neutrophils p=0.0024 (SPF<non-SPF) NS  
p=0.0068 
(SPF>non-SPF)  !  
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Figure 2: Developmental changes in T and B cell populations in infant macaques. Panel 
A: The average percentages ± SEM of B cells in PBMCs of SPF (open symbols) or non-SPF 
(closed symbols) infant macaques from birth to 48 weeks of age. The corresponding changes 
in absolute numbers of B cells are shown in Panel B. Panels C and D illustrate the changes in 
CD4+ and CD8+T cells within the CD3 T cell population during this time. Panel E shows the 
decline in the CD4:CD8 T cell ratio of SPF infants from birth to 40 weeks. Each symbol 
represents an individual SPF infant macaque; horizontal bars indicate the median value in 
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each age group. In Panel F, the average percentages ± SEM of Ki67+CD4+ (open circles) or 
Ki67+CD8+ (open triangles) T cells are graphically represented.. Statistically significant 
differences between groups are shown by capped lines and star symbols (*p<0.05, **p 
<0.01,***p<0.001). 
Table 2: Lymphocyte Populations 
Cell Population Median Cell Numbers/ µ l Blood (Minimum-Maximum No.) 
 
Infants Juveniles Infants vs. Juveniles Adults 
Juveniles vs. 
Adults 
SPF                                     n=23                    n=20                                              n=8 
All T cells (CD3+) 2633 (1373-4811) 
1257 
(336-1899) <0.0001 
486 
(194-1760) p=0.0031 
CD4+ T (CD3+CD4+) 1891 (1217-3598) 
828 
(459-1319) <0.0001 
124 
(15-734) <0.0001 
CD8+ T (CD3+CD8+) 832 (506-1843) 
397 
(209-1109) <0.0001 
363 
(179-1026) NS 
CD4:CD8 Ratio 2.3 (1.2-3.6) 
2.0 
(0.7-3.9) NS 
0.6 
(0.3-0.8) <0.0001 
B cells (CD20+) 1464 (649-2716) 
474 
(136-808) <0.0001 
224 
(97-736) p=0.0252 
Non-SPF                               n=11                  n=50                                              n=98 
All T cells (CD3+) 1657 (854-3676) 
1155 
(311-3730) NS 
745 
(103-2798) <0.0001 
CD4+ T (CD3+CD4+) 1169 (592-2531) 
753 
(195-2202) NS 
433 
(44-1606) <0.0001 
CD8+ T (CD3+CD8+) 488 (262-1145) 
310 
(99-1401) NS 
250 
(43-1276) 0.0139 
CD4:CD8 Ratio 2.2 (1.9-4.0) 
2.4 
(1.4-4.0) NS 
1.8 
(0.2-4.2) <0.0001 
B cells (CD20+) 824 (246-3472) 
1445 
(269-4317) NS 
366 
(69-1341) <0.0001 
Comparison of SPF versus Non-SPF Populations 
All T cells (CD3+) NS NS  NS  
CD4+ T (CD3+CD4+) NS NS  
p=0.0025 
(SPF < non-
SPF) 
 
CD8+ T (CD3+CD8+) NS 
p=0.0247 
(SPF > non-
SPF) 
 NS  
CD4:CD8 Ratio NS 
p=0.0132 
(SPF < non-
SPF) 
 
p=0.0132 
(SPF < non-
SPF) 
 
B cells (CD20+) NS 
p<0.0001 
(SPF < non-
SPF) 
 NS  !
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The post-birth immune development was also marked by phenotypic changes in T 
cell maturation. As expected, in the newborn, the majority of CD4+ and CD8+ T cells 
expressed a naïve phenotype, defined as CD3+CD45RA+CCR7+ or CD3+CD28+CD95- 
(Figure 3).  Even in SPF infants, the low, but continuous postnatal exposure to environmental 
(air- water-, and food-borne antigens) and pathogen-derived stimuli since birth led to a steady 
increase in both central memory (TCM) and effector/effector memory (TE/EM) T cells. 
Consistent with their primary function as helper CD4+ T cells or effector CD8+ T cells, 
respectively, T cell maturation and differentiation was more pronounced in CD8+ T cell 
population. At 1 year of age, close to 90% of the circulating CD4+ T cells still expressed a 
naïve T cell (T(N)) phenotype and less than 5% of all CD4+ T cells represented effector CD4+ 
T cells (Figure 3). In contrast, 15% of CD8+ T cells had developed into effector or effector 
memory T cells.  B cells matured similarly over the first year. There was a continuous 
decline in naïve (CD19+CD20+CD27-IgD+) B cells accompanied by a concurrent increase in 
unswitched (CD27+IgD+IgM+), switched (CD27+IgD-) and in double negative (IgD-CD27- ) B 
cells (Figure 4).  
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Figure 3: Memory T cell development in SPF infant macaques. The graphs show the 
longitudinal changes of naïve (open circles), central memory (stars), and effector/effector 
memory (closed triangles) in CD4+ (top row) and CD8+ T cells (bottom row) of infant SPF 
macaques of Indian (left panels, n=13) or Chinese (middle panels; n=10) origin. The 
combined average ± SEM data each for in CD4+ or CD8+ T cell subpopulation in Indian and 
Chinese infants are presented in the right-hand panels. 
 
 
 
 
 
 
	  	   40	  
 
 
Figure 4: B cell differentiation in infant macaques. The normal developmental changes in 
peripheral blood B cell populations from birth to 1 year of age in SPF (open symbols) and 
non-SPF (closed circles) infant macaques. Shown are mean values ± SEM for naïve, 
unswitched, switched and double negative B cell populations based on phenotypic 
characterization using CD27 and IgD.  
Non-SPF infants mirrored the developmental changes in the blood of SPF infants 
(Tables 1 and 2). Thus, in the absence of easily transmittable pathogens such as RhCMV, 
both SPF and non-SPF infant macaques peripheral blood cell populations matured in an 
analogous manner (Figures 1-4). The larger data variation in non-SPF infants was likely the 
result of the smaller group size because while we followed 11 non-SPF infant macaques until 
week 16, only 4 non-SPF macaques were analyzed from birth to one year.  It should be noted 
that the non-SPF infants were not serologically characterized for infection status.  However, 
the non-SPF infants were raised under identical conditions (i.e. separation from the dam at 
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birth and nursery reared away from infected cohorts) that the CNPRC has used to generate 
the SPF cohort.  Therefore, it is presumed that the non-SPF infants were, in fact, SPF.  We 
did not observe any differences in immune maturation between Indian or Chinese macaques 
(Figure 3 as a representative example and data not shown), and thus concluded that macaque 
origin did not affect early immune development of peripheral blood cells. 
RhCMV immunity in juvenile and adult macaques 
At one year of age, SPF and non-SPF infant macaques were transferred to separate 
SPF or non-SPF outdoor field cages, respectively. Thus, during the development from infants 
into adolescent and adult macaques, SPF and non-SPF macaques continued to be exposed to 
similar environmental pathogens. Because SPF macaques were bred to be free of RhCMV, 
juvenile or adult SPF animals could not transmit RhCMV to younger animals upon 
cohabitation.  Continued regular monitoring confirmed that RhCMV remained undetectable 
in all animals of the SPF colony. In contrast, the transition of the young non-SPF macaques 
to a cohabitation with older non-SPF macaques prompted their exposure to pathogens 
endemic within the non-SPF colony, such as RhCMV.  
We have previously documented that about >90% of conventional non-SPF macaques 
housed in outdoor corrals become infected with RhCMV between 5-12 months of age (13), 
(149), (161). Moreover, virological surveys revealed that the frequency and magnitude of 
viral shedding on naturally RhCMV infected animals were higher in younger compared to 
adult monkeys (Oxford and Barry, unpublished observations). This could explain why many 
adult monkeys in our study had undetectable virus in the saliva at a single time point. When 
we tested juvenile non-SPF macaques, we could detect RhCMV in saliva (Figure 5A). In fact, 
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juvenile non-SPF macaques shed RhCMV more frequently (78% vs. 28%), and at 
significantly higher titers (5.47 x 104 copies/ml; 95% CI: 6665 to 102833) than adult non-
SPF macaques (2.31 x 103 copies/ml; 95% CI: 348 to 4265, respectively) (Figure 5A). 
Furthermore, all juvenile non-SPF macaques included in the current study had seroconverted 
and developed neutralizing antibodies to RhCMV glycoprotein B. The RhCMV gB–specific 
neutralizing antibody titers of the juvenile macaques were comparable to those of the adult 
non-SPF macaques (Figure 5B), suggesting that once maximum neutralizing antibody titers 
were reached, they persisted. This result, similar to HCMV in humans, is consistent with the 
lifelong persistence of RhCMV in the animals without causing disease, despite occasional 
virus shedding (13). Albeit neutralizing antibody titers were weakly associated with RhCMV 
shedding in juvenile macaques (Figure 5C), such a correlation was not observed in the 
infrequently shedding adult macaques (Figure 5D). Thus, we concluded that the magnitude of 
the neutralizing antibody response was not correlated to antigen load in the animals. 
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Figure 5: Viral and immune parameters of RhCMV infection. Panel A shows the 
quantity of RhCMV shed orally by juvenile (n=50, filled triangles) or adult (n= 98, filled 
hexagon) non-SPF macaques. Each symbol represents an individual animal; horizontal lines 
indicate the median of the age-group. In Panel B, neutralizing plasma antibody titers for 
RhCMV-infected juvenile and adult mcaques are shown.  The legend is similar to Panel A.  
Neutralizing antibodies were correlated with oral RhCMV shedding in juvenile (Panel C) or 
adult (Panel D) macaques. Statistically significant differences are indicated by P values. 
In contrast to neutralizing antibodies, RhCMV-specific T cell responses further 
increased with age. In response to in vitro stimulation of PBMCs with RhCMV lysate, 
juvenile non-SPF macaques produced only low levels of cytokines (Figure 6).  Although not 
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every animal produced all cytokines, each juvenile animal produced at least one cytokine in 
response to RhCMV lysate stimulation. Consistent with the RhCMV-induced expansion of 
memory T cells with age, adult macaques produced significantly higher levels of certain 
cytokines, in particular the pro-inflammatory cytokines IFNγ, IL6 and IL1β, than juvenile 
non-SPF rhesus macaques (Figure 6). Median values of TNFα and RANTES were also 
higher in adults than in juveniles, but this difference did not reach statistical significance 
(data not shown). These results were consistent with the previously documented expansion of 
RhCMV-specific T cells in macaques and HCMV-specific T cells in humans (117), (152), 
(153).  
	  	   45	  
 
Figure 6: Cytokine responses to in vitro RhCMV stimulation. Culture supernatants 
collected after rhesus PBMCs from juvenile (n=10) or adult (n=10) non-SPF macaques were 
stimulated for 48 hours with RhCMV lysate and analyzed by multiplex analysis. Each graph 
represents the amount of a specific cytokine produced in response to RhCMV lysate 
stimulation expressed in pg/mL. Each symbol is representative of a single animal and 
horizontal bars indicate median cytokine levels for each age group. Statistically significant 
differences are indicated by P values. 
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SPF status modulates immune maturation in juvenile and adult macaques  
Having confirmed that RhCMV infection was one distinguishing factor between SPF 
and non-SPF juvenile and adult macaques, we compared lymphocyte maturation and function 
between these two groups of macaques to determine whether chronic RhCMV infection was 
associated with modulated immune development or responsiveness.  
Lymphocyte numbers in juvenile SPF macaques were significantly lower (p<0.0001) 
than in 1-year old infant macaques (Table 1). Both T and B cells were significantly decreased 
in SPF juvenile compared to SPF infant macaques. This trend was not observed in non-SPF 
macaques, with non-SPF juvenile macaques having significantly higher lymphocyte numbers 
(median: 3037/ml blood) than juvenile SPF macaques (median: 1949/ml blood; Table 1). 
This difference in absolute lymphocyte numbers appeared to be primarily the result of higher 
B cell numbers in non-SPF juvenile macaques, because T cell frequencies were comparable 
between SPF and non-SPF juvenile macaques (Table 2). Interestingly, juvenile SPF 
macaques had fewer differentiated B cells than non-SPF juvenile macaques (Figure 7). It is 
tempting to speculate that the higher frequencies of switched and double negative B cells in 
non-SPF juveniles could be related to the development of RhCMV-specific antibodies in 
these animals, but further studies would be required to confirm this hypothesis. Over time, 
these differences in peripheral blood B cell maturation between SPF and non-SPF macaques 
waned and adult SPF and non-SPF macaques showed similar percentages of naïve and 
differentiated B cells. 
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Figure 7: Memory B cell development in juvenile and adult macaques. B cell sub 
populations as described in Figure 4 were analyzed in SPF juvenile (n=8) and adult (n=8) 
macaques and compared to the same populations in blood of non-SPF juvenile (n=18) and 
adult (n=8) macaques. Open and closed symbols represent SPF and non-SPF macaques, 
respectively. Horizontal lines indicate median values per age groups. Statistically significant 
differences between groups are shown by capped lines and star symbols (*p<0.05, **p 
<0.01,***p<0.001). 
Despite similar total T cell frequencies, differences between SPF and non-SPF 
macaques started to emerge when we examined T cell subpopulations in more detail. From 
infant to adult age, there was a significant decrease in CD4+ T cell numbers of SPF and non-
SPF macaques (Table 2). CD8+ T cell frequencies seemed to reach steady state level in 
juvenile macaques. More importantly though, as the individual animals became exposed to a 
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greater number of various environmental and pathogenic stimuli with age, the maturation 
status of their T cells changed.  Compared to infant macaques, juvenile and adult macaques 
had fewer numbers of naïve T cells and increasing numbers of more differentiated T cells 
(Figure 8). As expected, we observed a similar age-related decline in naïve CD4+ 
(CD45RA+CD95-) and CD8+ (CD45RA+CD28+) T cell populations of SPF and non-SPF 
macaques (Figure 8). However, naïve CD4+CD45RA-CD95- T cells were higher in SPF 
compared to non-SPF adult macaques, whereas the more differentiated effector-like 
(CD45RA+/-CD95+) CD4+ T cells were higher in non-SPF adults (Figure 8). Differentiated 
CD8+ T cell subsets did not differ between SPF and non-SPF adult macaques, but juvenile 
non-SPF macaques had more CD45RA-CD28+ CD8+ T cells (Figure 8).  Thus, in addition to 
age-related changes in B and T cell populations between SPF and non-SPF macaques we also 
observed differences in T and B cell phenotypes, suggesting that both age and chronic viral 
infection, i.e. RhCMV, influenced B cell maturation and the differentiation of CD4+ and 
CD8+ T cell subsets in peripheral blood. 
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Figure 8: Comparative analysis of memory T cell populations in SPF and non-SPF 
juvenile and adult macaques. Percentages of naïve (left panels), and various differentiated 
(middle and right panels) CD4+ (top row) and CD8+ (bottom row) T cell populations in 
juvenile and adult SPF and non-SPF macaques. Each symbol represents an individual animal 
with horizontal bars indicating the median value for each group. Statistically significant 
differences between groups are shown by capped lines and star symbols (*p<0.05, **p 
<0.01,***p<0.001). 
Assessment of T lymphocyte function in relation to age and RhCMV serostatus 
One important question that evolved from these data was how age-associated T cell 
maturation was reflected in T cell function, and specifically, whether and how chronic 
RhCMV infection would affect the magnitude or quality of T cell responses.  Table 3 
summarizes the development of single cytokine responses in CD4+ and CD8+ T cells from 
birth to one year of age in SPF infant macaques. Infant CD4+ T cells generally exhibit a Th2-
biased response.  Indeed, in the first 4 weeks of life, few CD4+ T cells from SPF infant 
macaques produced IFNγ, the principle Th1 characterizing cytokine, in response to 
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polyclonal T cell stimulation.  IFNγ-producing CD4+ T cells gradually increased from 
<0.015 % in the first month to >0.1% of total CD4+ T cells by 6 months of age (gray-
gradient) (Table 3; p=0.002). This was consistent with the gradual increase in effector T cells, 
which were the primary cytokine-producing T cell population (data not shown). However, 
despite a similar increase of effector CD8+ T cells from birth to one year, the majority of 
animals had equivalent CD8+ T cell IFNγ responses ranging from 0.1 to 1% throughout the 
first year (Table 3, p=0.111).  These data, combined with the fact that newborns were 
generally able to mount good IL2 and TNFα CD4+ T cell responses (Table 3), were 
indicative of CD4+ T cell-intrinsic factors that could interfere with IFNγ production in 
neonates. In fact, TNFα responses did not change significantly over time, and IL2-producing 
CD4+ and CD8+ T cells actually declined in the first year (p<0.001; Table 3).  
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Table 3: Cytokine Responses in infant T cells 
 
Age 
(weeks) 
Animal 
No. 
Cytokine-producing CD3+CD4+T Cells (%) Cytokine-producing CD3+CD8+T Cells (%) 
<0.015 ≥0.015<0.1 ≥0.1<1.0 ≥1.0<10.0 ≥10.0 <0.015 ≥0.015<0.1 ≥0.1<1.0 ≥1.0<10.0 ≥10.0 
IFN-γ  
0 13 9 4 0 0 0 2 3 8 0 0 
2 21 10 6 4 1 0 4 5 9 3 0 
4 20 5 8 7 0 0 5 0 8 7 0 
6 16 2 9 5 0 0 0 1 9 6 0 
8 22 3 10 9 0 0 0 1 16 5 0 
10 23 7 13 3 0 0 0 5 17 1 0 
12 22 4 13 5 0 0 2 4 13 3 0 
16 21 4 13 3 1 0 2 1 16 2 0 
20 22 4 13 5 0 0 0 6 14 2 0 
24 22 1 11 10 0 0 1 2 19 0 0 
28 22 3 8 9 0 0 0 2 14 6 0 
32 21 3 5 10 3 0 1 2 14 4 0 
36 20 1 5 11 3 0 0 2 13 5 0 
40 17 0 2 14 1 0 0 1 12 4 0 
44 19 1 3 14 1 0 1 0 14 4 0 
48 18 3 5 10 0 0 0 2 15 1 0 
IL-2 
0 13 0 0 2 4 7 1 0 1 7 4 
2 21 1 3 1 11 5 2 2 2 11 4 
4 20 2 3 0 6 9 4 1 2 9 4 
6 16 0 0 1 6 9 0 0 0 12 4 
8 22 0 0 1 8 13 0 0 2 15 5 
10 23 0 0 5 13 5 0 0 3 16 4 
12 22 1 2 4 9 6 1 0 4 16 1 
16 21 1 2 4 10 4 1 1 0 15 4 
20 22 1 1 5 9 5 1 1 4 16 0 
24 22 2 2 7 11 0 2 1 10 9 0 
28 22 2 4 1 13 2 3 4 4 9 0 
32 21 1 3 4 10 3 4 4 5 3 1 
36 20 3 2 6 9 0 3 7 6 3 0 
40 17 8 1 4 4 0 4 4 5 3 1 
44 19 3 6 5 5 0 3 7 6 3 0 
48 18 12 2 1 3 0 10 4 1 3 0 
TNF-α 
0 13 1 0 3 4 5 0 1 3 6 3 
2 21 4 2 8 7 0 2 1 7 11 0 
4 20 4 3 7 6 0 4 1 5 10 0 
6 16 0 0 7 9 0 0 0 7 9 0 
8 22 0 1 5 15 1 0 0 9 12 1 
10 23 0 0 3 13 7 0 0 2 19 2 
12 22 0 1 2 14 5 0 0 3 16 3 
16 21 0 0 3 13 5 0 0 2 16 3 
20 22 1 1 3 11 6 1 1 3 15 3 
24 22 2 0 2 16 2 2 0 2 17 1 
28 22 1 1 7 9 4 1 1 8 11 1 
32 21 1 2 10 7 1 1 0 10 10 0 
36 20 5 0 10 4 1 4 1 8 7 0 
40 17 2 1 1 10 3 3 0 2 12 0 
44 19 0 0 0 12 7 0 0 3 16 0 
48 18 0 0 1 10 6 0 0 5 12 1 !
 
To measure physiologically more relevant responses, we stimulated SPF infant 
PBMC with anti-CD3 and anti-CD28 antibodies to activate T cells directly through the T cell 
receptor (TCR).  Supernatants were collected at 24 hours and analyzed for cytokines 
important in T cell activation and CD4+ T helper cell lineage differentiation.  This experiment 
included 8 SPF infants that ranged from 3 to 9 weeks in age and 8 additional 10 to 16 week-
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old SPF infants.  As we could not detect any statistically significant differences between 
these two groups (data not shown), we combined the data from both infant groups (Total 
n=16) and compared them to cytokine levels induced by TCR stimulation in SPF juvenile 
and SPF adult macaques.  There was an age-dependent increase in cytokine responses to 
TCR stimulation. Infants had significantly lower IFNγ, IL17A, IL10, and IL6 responses than 
SPF juvenile macaques (Figure 9).  Although there was also a trend towards higher IL2 and 
TNFα levels in juvenile macaques, these differences did not reach statistical significance.  
Median cytokine responses further increased when SPF juvenile macaques were compared to 
SPF adult macaques. In addition to these quantitative changes, the quality of the response 
differed between age groups.  Consistent with a Th2-biased response of infants, the ratio of 
IFNγ:IL4 was lowest in infant and highest in adult SPF macaques (Figure 10). An 
impairment of Th responses was further supported by the fact that the IFNγ:IL10 was 
significantly lower in infant compared to adult SPF macaques.  
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Figure 9: TCR-induced cytokine responses in PBMCs of SPF macaques of different age 
groups. The various graphs show the production of specific cytokines by PBMCs of infant, 
juvenile and adult SPF macaques after 24 hours of stimulation with anti-CD3 and anti-CD28 
antibodies. Data are expressed in pg per milliliter (pg/ml) of culture supernatant. Cytokine 
levels between the three distinct age groups were compared using the Kruskal-Wallis test and 
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P values are indicated in the upper left hand corner of each graph. Statistical significant 
differences between two groups by subsequent Dunn’s comparison are shown with capped 
lines and star symbols (*p<0.05, ** p<0.01,*** p<0.001).  
 
 
Figure 10: Changing cytokine ratios in response to TCR stimulation with age. 
Consistent with lower IFNγ responses in infants, the raio of IFNγ:IL4 or IFNγ:IL10 increase 
with age (left top and bottom graphs, respectively), whereas no age-related differences were 
observed in the IL2:IL4 or the TNFα:IL10 ratios (right top and bottom graphs, respectively). 
Statistical significant differences between two groups by subsequent Dunn’s comparison are 
shown with capped lines and star symbols (*p<0.05, ** p<0.01,*** p<0.001). 
To assess the potential impact of RhCMV infection on T cell function, we compared 
cytokine responses between SPF and non-SPF juvenile macaques after Con A stimulation. 
Most pro-inflammatory cytokines, including IL6, TNFα (Figure 11A), IL1β, and TNFβ (data 
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not shown) were expressed at higher levels in non-SPF than in SPF juvenile macaques. 
Although SPF juveniles produced significantly more IL12 and had a higher IL12:IL10 ratio 
than non-SPF juveniles (Figure 11B), the SPF juveniles showed lower IFNγ responses 
(Figure 11A). The significantly lower ratio of IFNγ:IL4 in SPF compared to non-SPF 
juvenile macaques was indicative of a more Th2-dominant response in the SPF animals, 
whereas T cell responses in non-SPF juvenile macaque seemed to be more biased towards 
inflammatory responses (Figure 11).  Adult non-SPF macaques showed similar responses to 
juvenile non-SPF macaques. Although the adult non-SPF macaques produced significantly 
higher levels of some anti-inflammatory cytokines (e.g. IL10, IL1Rα) in response to Con A 
stimulation (Table 4), they also produced more TNFα and the Th1-associated chemokine 
RANTES (Table 4). These data were reminiscent of the increased induction of some 
inflammatory cytokine in RhCMV-stimulated PBMCs of adult compared to juvenile non-
SPF macaques (Figure 6). The persistence of activated T cells into adulthood was further 
supported by the fact that adult CD4+ T cells contained similar frequencies of CCR5 and 
CD25 positive CD4+ T cells compared to juvenile non-SPF macaques (Figure 12). 
Frequencies of CXCR3-positive CD4+ T cells were even higher in adult macaques, consistent 
with their further expansion of memory CD4+ T cells (Figure 12).  
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Figure 11: Comparative cytokine responses of juvenile SPF and non-SPF macaques to 
Con A stimulation. Panel A. The individual graphs show the production of specific 
cytokines in PBMC of SPF or non-SPF juvenile  macaques after in vitro stimulation with 
Con A. Cytokines were measured in culture supernatants at 48 hours. Panel B shows how the 
cytokine ratios of IL12:IL10 and IFNγ:IL4 differ between juvenile SPF and non-SPF 
macaques. Each symbol represents an indivudal animal; horizontal lines indicate the median 
of the age-group. Capped lines with P values indicate statistically significant differences 
between the two groups determined by Mann-Whitney test (*p<0.05, **p <0.01,***p<0.001).  
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Table 4. Cytokine Responses To In Vitro Con A Stimulation  
Cytokine 
Median Cytokine Levels in pg/ ml (Minimum-Maximum) 
SPF Juveniles Non-SPF Juveniles SPF vs. Non-SPF Juveniles Non-SPF Adults 
Non-SPF Juveniles 
vs. Adults 
Inflammatory 
IL-6 58.0 
(8.6-1451) 
647.7 
(207.6-1778) p<0.05 
1267.0 
(268.2-2253) NS 
TNF-α 1198.0 
(48.2-4103) 
3436.0 
(1260.0-6368.0) p<0.001 
6181.0 
(2246-9517) p<0.05 
IL-1β 23.4 
(0.3-71.4) 
113.7 
(25.5-259.0) p<0.001 
226.3 
(80.9-795.9) NS 
TNF-β 334.7 
(31.5-1089.0) 
1185.0 
(104.6-2307.0) 
p<0.001 753.2 
(232.3-1465.0) 
NS 
IL-12p40 1174.0 
(592.9-2068.0) 
167.3 
(15.1-260.8) p<0.0001 
215.8 
(96.2-606.6) NS 
IL-15 4.0 
(1.9-8.9) 
11.3 
(0-16.2) p<0.001 
11.1 
(7.6-15.6) NS 
CXCL-10 33.0 
(16.2-45.0) 
13.1 
(3.0-23.4) p<0.0001 
10.6 
(0.1-22.0) NS 
Anti-Inflammatory 
IL-10 53.5 
(3.5-974.9) 
171.2 
(20.0-453.0) p=0.0251 
489.7 
(72.3-978.1) p=0.0115 
IL-1Rα 6073.0 
(1775-15352) 
529.7 
(48.2-887.4) p<0.0001 
937.8 
(266.6-3574.0) p=0.0279 
Th differentiation 
IL-2 2451.0 
(19.4-21229.0) 
4892.0 
(40.6-7656.0) 
NS 3511.0 
(814.1-23975) 
NS 
IFN-γ 681.0 
(5.2-5832.0) 
16058.0 
(2704-20164) p<0.001 
19656 
(14315-20941) NS 
IL-4 1.3 
(0.3-7.3) 
3.9 
(1.1-8.6) p<0.05 
9.3 
(4.2-21.7) p=0.0015 
IL-9 259.2 
(126.2-512.0) 
20.5 
(9.8-47.9) p<0.0001 
38.2 
(24.2-103.3) p=0.0089 
Chemokines 
RANTES 11017.0 
(800.3-37070) 
970.5 
(151.8-2041.0) p<0.0001 
1818.0 
(930.2-3434.0) p=0.0089 
Eotaxin 13.3 
(4.1-24.1) 
21.3 
(8.0-31.2) p=0.0301 
21.7 
(1.5-25.5) NS 
Cytokine Ratios 
IL-12:IL-10 24.1 
(0.8-326) 
0.7 
(0.2-1.1) p<0.001 
0.3 
(0.2-0.8) NS 
IFN-γ:IL-4 508.2 
(17.8-8997.0) 
4329.0 
(484.6-12917) 
p<0.001 2032.0 
(886.0-4871.0) 
p=0.0350 
IL-1β:IL-1Rα 0.004 
(0.0-0.0096) 
0.36 
(0.04-3.69) p<0.0001 
0.27 
(0.06-0.88) NS 
RANTES:Eotaxin 611.3 
(64.1-8074.0) 
41.0 
(16.7-158.1) p<0.0001 
79.8 
(52.9-1353.0) p=0.0435 !  
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Figure 12: CD4+ T cell activation in relation to SPF status and age. Data in Panel A 
demonstrate that CD4+ T cell activation as measured by the percentage of CCR5-positive 
CD4+ T cells is higher in non-SPF compared to SPF juvenile macaques. In contrast, 
frequencies of CD25-positive CD4+ T cells are higher in SPF juveniles, likely because CD25 
is not only a T cell activation marker, but also expressed on regulatory T cells. In Panel B , 
frequencies of CCR5- and CD25-positive CD4+ T cells do not differ between non-SPF 
juvenile and adult mcaques. However, adult non-SPF mcaques have higher frequencies of 
CXCR3-positive CD4+ T cells in their blood. Each symbol represents an individual animal, 
horizontal bars represent the median value per group. Statistical significant differences are 
indicated by P values.  
DISCUSSION  
First and foremost, the goal of the study was to provide evidence that the available 
SPF and non-SPF colonies of rhesus macaques can serve as a tool to study the impact of 
chronic infections such as HCMV on the immune system. Particularly, we aimed to show 
that chronic RhCMV infection could modulate immune responses throughout the lifespan of 
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the host. Our approach was threefold. We generated normative data for neonatal and infant 
immune development of peripheral blood cell populations of SPF and non-SPF macaques 
from birth throughout the first year of life. Under the controlled housing conditions we 
applied, namely limited pathogen exposure and identical diet, SPF status and origin of the 
infant did not influence neonatal and infant immune development. Indirectly, these results 
imply that SPF breeding of rhesus macaques is not associated with major inherent changes in 
their genetic immune repertoire. This is important as rhesus macaques are widely used as 
animal model for human diseases. We would anticipate though that infants raised outdoors 
and infants that are breastfed by their mothers would differ in their immune development 
from the nursery SPF and non-SPF infants included in the current study due to a different 
microbial flora at mucosal sites and an earlier and broader pathogen exposure (110, 121), 
(135). In fact, our comparison of juvenile SPF and non-SPF macaques demonstrates that the 
infection with RhCMV could modulate host immune responses.  Finally, our data show that 
changes introduced in certain immune parameters by RhCMV of juvenile macaques will 
persist in the chronically infected animal. 
The analysis of blood cell populations from birth to 1 year shows that the infant 
immune system undergoes tremendous changes after birth. Cell populations changed in 
frequencies and in their relative abundance to each other. Our results in infant macaques are 
remarkably similar to normal developmental changes observed in human infants (142), (38). 
Generally, homeostatic levels were reached by about 3 months of age. Functional maturity of 
the various cell populations, however, required more time. Here, we specifically focused on 
T cell immunity. Although neutralizing antibodies are likely essential for the prevention of 
HCMV or RhCMV infection, it is well established that CD4+ and CD8+ T cell responses are 
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critical in controlling HCMV infection in humans and RhCMV infection in rhesus macaques 
(132), (117), (152), (145, 147) Consistent with previous reports, we observed minimal IFNγ 
production by infant CD4+ T cells in the first few months of life (143). There was a gradual 
significant increase in the ability to produce IFNγ, a cytokine important for CD4+ Th1 and 
CD8+ T cell antiviral responses, in the first year of life. Interestingly though, inflammatory 
cytokines like TNFα could be produced evenly well by infant CD4+ and CD8+ T cells at birth 
and at 1 year. Overall, infant T cells responded with lower cytokine production to unspecific 
as well as TCR-specific stimulation compared to juvenile and adult macaques, independent 
of their SPF status. Higher cytokine responses with age were consistent with increasing 
frequencies of differentiated effector and memory T cells. As expected, these normal 
developmental changes were observed in both SPF and non-SPF, RhCMV infected animals. 
Interestingly though, the acquisition of RhCMV in juvenile non-SPF macaques appeared to 
be associated with some deviation in immune parameters between SPF and non-SPF 
macaques. Juvenile non-SPF macaques had higher frequencies of differentiated B cell 
subsets compared to SPF juveniles. Although, our studies were not designed to determine a 
causative relationship, one could speculate that the induction of RhCMV-specific antibodies 
was one factor driving the development of more mature B cells in non-SPF macaques. As has 
been reported previously, chronic RhCMV infection is associated with memory T cell 
expansion. Indeed, our data confirm that the total effector CD4+ T cell population is 
significantly higher in adult SPF than in adult non-SPF macaques. While we did not 
determine the actual frequencies of RhCMV-specific memory T cells, we assessed the 
functional response of RhCMV-specific T cells.  Consistent with memory T cell inflation, we 
observed higher cytokine responses in adult compared to juvenile non-SPF macaques. 
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Unspecific T cell stimulation also resulted in higher production of pro-inflammatory 
cytokines in adult compared to juvenile macaques, but the ratio of pro-to anti-inflammatory 
cytokines decreased slightly with age. 
Altered T cell responsiveness with aging was not restricted to RhCMV-specific T cell 
responses. In comparison to SPF macaques, the response of non-SPF (RhCMV-infected) 
macaques to polyclonal T cell stimulation showed a bias towards higher inflammatory 
cytokine induction. This bias was most pronounced when juvenile SPF and non-SPF animals 
were compared. We hypothesize that the active replication of RhCMV in juvenile macaques, 
as evident in their more frequent shedding patterns of RhCMV in oral fluids, contributed to 
the more inflammatory cytokine profile of non-SPF compared to SPF juvenile macaques. 
Furthermore, these qualitatively distinct responses in juvenile macaques were indicative of 
early predisposition of juvenile RhCMV-infected animals to “inflammaging” in adult 
macaques, and supported our hypothesis that chronic RhCMV infection could broadly 
modulate host immune responses.  To define the underlying mechanisms leading to 
inflammaging, future longitudinal and comparative studies between animals of SPF and non-
SPF colonies are needed. Such studies could address questions examining (i) whether 
RhCMV infection leads to epigenetic changes in T or B cell populations, (ii) whether 
immune modulation would be reversible if recognized earlier in life, (iii) which processes 
regulate and control inflammaging, (iv) how normal aging or immunosenescence differ from 
inflammaging, and (v) whether genetic factors contribute to inflammaging in chronically 
infected humans. Further, these two cohorts of macaques can be used to assess vaccine and 
adjuvant responsiveness in relation to both aging and persistent pathogen loads. We now 
have large cohorts of SPF and non-SPF macaques available to perform a thorough analysis of 
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immune modulation in relation to normal aging in the context of viral infection in blood and 
relevant tissues. 
In summary, our results confirm that RhCMV infection in macaques is highly similar 
to HCMV infection in humans and that the development of the major immune cell 
populations in blood occurs analogous to humans. The results of the current study support the 
further exploration of rhesus macaques as a model system to study the impact of chronic viral 
infections, specifically RCMV infection, on the modulation of host immune responses on 
otherwise, healthy monkeys and during aging using the now available SPF and non-SPF 
rhesus macaque colonies. RhCMV, similar to humans, is naturally acquired during early 
childhood and persists in rhesus macaques throughout their lifespan (13), (85), (112) (114), 
(161). Previously, we demonstrated that RhCMV-specific binding and neutralizing 
antibodies develop during primary infection (163).  Our current data show juvenile and adult 
non-SPF macaques had comparable titers of RhCMV-specific neutralizing plasma antibody 
titers. These data suggest that once elicited, neutralizing antibodies to RhCMV persist at high 
levels. Furthermore, we concluded that the magnitude of the neutralizing antibody response 
was not dependent on antigenic load because we observed significantly higher and more 
frequent viral shedding in juvenile compared to adult RhCMV-infected macaques.  In 
contrast, there was an age-dependent increase in RhCMV-specific T cell responses, a result 
consistent with the previously reported memory inflation in HCMV and RhCMV infection 
(71, 112, 113).  
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CHAPTER 31. USE OF SPECIFIC-PATHOGEN-FREE (SPF) RHESUS MACAQUES 
TO BETTER MODEL ORAL PEDIATRIC CYTOMEGALOVIRUS INFECTION 	  
 
 
OVERVIEW 
The immune system of infants undergoes many developmental changes after birth 
and these changes may affect their ability to respond to viral pathogens like human 
cytomegalovirus (HCMV). A member of the β-herpes family of viruses, HCMV establishes a 
lifelong infection in an immunocompetent host without clinical symptoms. Interestingly, 
HCMV-infected children shed virus longer and in higher titers than adults. The limited 
functional capacity of the infant immune system contributes to infants’ reduced ability to 
control viral replication compared to adults. As predicted, infant rhesus macaques were 
rapidly infected via the oral route when compared to adults. Moreover, infant T cell 
responses were of lower magnitude compared to adult macaques. Lastly, viral shedding was 
observed more frequently in the infants’ bodily fluids compared to their adult counterparts. 
The utility of this nonhuman primate model of infant RhCMV will improve our 
understanding of the temporal development and differences of the infant immune system’s 
response to viral pathogens and potentially provide insights into the design of effective 
vaccines tailored to infants early in life. 
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INTRODUCTION  
Worldwide, human cytomegalovirus (HCMV) infection is the most common 
congenital infection, affecting ≈0.7% of all fetuses. Congenitally infected infants can suffer 
lifelong neurological sequelae and clinically healthy babies at birth can develop neurological 
complications in the first years of life (50), (66), (147). In the United States (US), 0.5-2% of 
all infants acquire HCMV in utero. Seronegative young infants can acquire HCMV through 
BM or in day care settings, e.g. through HCMV-contaminated saliva on toys (134), (90), 
(101). Similar to HCMV-infected adults, infants generally do not develop clinical symptoms 
upon HCMV acquisition, but, in contrast to adults, shed virus for prolonged periods of time 
(101). As their infection goes largely unnoticed, HCMV-infected children can transmit the 
virus to seronegative pregnant women who either have or do not have preconceptional 
immunity to HCMV. It is now well established that HCMV can re-infect HCMV-immune 
women. In the absence of an HCMV vaccine, interventions aimed at stopping or reducing 
HCMV shedding in infants could provide an effective means of preventing congenital 
HCMV infection. 
The host factors responsible for prolonged viral shedding in infants are only poorly 
understood. To overcome sample limitations from young children, we sought to develop an 
infant rhesus CMV infection model because RhCMV infection in adult macaques is highly 
similar to human HCMV infection (15), (85). Previously, a direct comparison of RhCMV-
specific immune responses between infant and adult macaques in correlation to virological 
outcome was not possible, because RhCMV is ubiquitous in macaque colonies and >90% of 
animals have seroconverted by 6 months of age. The generation of Specific Pathogen Free 
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(SPF) macaque colonies in which animals are bred to be free of multiple viruses, including 
RhCMV, now enables controlled RhCMV pathogenesis studies in different age groups (14).  
MATERIALS AND METHODS 
Animals and Rhesus Cytomegalovirus (RhCMV) Infection 
 Infant and adult rhesus macaques (Macaca mulatta) were obtained from the specific 
pathogen-free (SPF) colony at the California National Primate Center (CNPRC). These 
animals were seronegative for the Rhesus Cytomegalovirus (RhCMV) prior to study entry, 
and also seronegative for simian herpes B virus, simian immunodeficiency virus (SIV), 
simian retrovirus (SRV), simian T-cell lymphotropic virus type 1 (STLV1), simian foamy 
virus (SFV) and rhesus rhadino virus (RRV). The infant macaques were nursery reared and 
adult animals were housed indoors for the duration of the study. All animal procedures were 
approved by the University of California at Davis Institutional Animal Use and Care 
Committee (IACUC) and in accordance with the guidelines provided by the American 
Association for Accreditation of Laboratory Animal Care Standards.  
 RhCMV infection was performed via oral administration of a natural RhCMV isolate 
with a blunted syringe at 1x 106 PFU per ml, a dose based on successful infection of adult 
monkeys (unpublished data, Dr. Peter Barry). The oral inoculation route was chosen to 
mimic mother-to-child transmission of HCMV in humans by breast milk (BM). Infant 
macaques (n=5) were inoculated at 1 month after birth. Adult macaques (n=3) were between 
4 and 5 years of age at the time of RhCMV exposure. The animals were followed for 1 year 
and then released back into the non-SPF colony where RhCMV infection is ubiquitous. 
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Sample collection and processing 
 Animals were anesthetized with 10mg/ml ketamine-HCl prior to all sample 
collections. EDTA blood samples were collected longitudinally every 2 weeks for 12 weeks 
and then once a month for 1 year. Plasma was harvested by centrifugation and stored at -
80°C for antibody measurement and virus quantitation. Saliva was harvested by placing 2 
sterile Weck-Cel spear sponges soaked with PBS (Beaver Visitec International, Waltham, 
MA) between the gums and cheeks on each side. Saliva supernatant was separated by 
centrifugation and stored immediately at -80°C. Urine was collected via cystocentesis, the 
total volume was recorded and immediately stored -80°C. Peripheral blood mononuclear 
cells (PBMCs) were isolated from whole blood via density centrifugation using Lymphocyte 
Separation Medium (LSM) (MP Biomedicals, Solon, OH) as described (91). 
RhCMV-specific T cell response 
To measure RhCMV-specific T cell responses, PBMCs were resuspended with RPMI 
1640 media (Cellgro, Manassas, VA) supplemented with 10% heat-inactivated FBS (Cellgro, 
Manassas, VA) and L-glutamine-penicillin-streptomycin antibiotic cocktail (Sigma, St Louis 
MO) at 1.0 x106 cells/ml. RhCMV antigens pp65 (lower matrix phosphoprotein), IE1 
(immediate early antigen), and whole virus lysate were used at concentrations of 1.0µg/ml, 
5.0µg/ml and 5.0µg/ml, respectively. Negative control received no stimuli (media only). 
PBMC stimulated with phorbol 12-myristate 12-acetate (PMA) (Sigma) at 10ng/ml and 
Ionomycin (I) (Sigma) at 125ng/ml served as a positive control. The cell cultures were 
incubated for 6 hours at 37°C, 5% CO2 with Brefeldin A at 3.0µg/ml being added after the 
first hour (eBioscience, San Diego, CA). At the end of the culture period, cells were stained 
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for surface antibodies, fixed, and permeabilized for intracellular cytokine staining as 
described previously (91).  
Flow cytometric analysis 
The following antibody panels were used to determine T cell activation: CD3 (SP34-
2)-Pacific Blue CD4 (L200)-PerCPCy5.5, CD8 (RPA-T8)-PeCy7 and Ki67 (B56)-FITC 
(B56), T cell differentiation: CD3, CD4, CD8, CD45RA (5H9)-APC, CCR7 (3D12)-PeCy7, 
or T cell cytokine production: CD3, CD4, IL2 (MQ1-17H12)-APC, IFNγ (B27)-Alexa700 
(B27), TNFα (MAb11)-PeCy7 (eBiosciences), and CD107a/b (H4A3/H4B4)-FITC. 
Antibodies were purchased from Beckton-Dickinson (BD) unless indicated otherwise. Flow 
cytometric samples were acquired on the LSRII flow cytometer (BD Biosciences, San Jose, 
CA).  A minimum of 300,000 events were acquired for antigen-specific responses and 30,000 
events for T cell activation. FlowJo Software was used to analyze the data (Tree Star, 
Ashland, Oregon). The ability of the CD4+ and CD8+ T cells to produce cytokines were 
evaluated using the following logical gating strategy: PBMC gate (FSC-A vs. SSC-A), 
Singlets (FSC-H vs. FSC-A), T cells (CD3+CD4+, CD3+CD4- = CD8+ T), followed by gating 
for IFNγ, IL2 and/or TNFα (within CD4+ or CD8+ T cells. Boolean gating was applied to 
assess the frequency of multifunctional T cells. Antigen-specific CD4+ or CD8+ T cell 
responses were considered positive if their frequencies were at least 2 times higher than in 
unstimulated PBMC and if their actual value was ≥0.015%.  
RhCMV antibody measurement  
RhCMV-specific binding antibodies were determined by ELISA as previously 
described (85), (163). Briefly, 96-well Immulon 4HBX plates (Fisher-Thermo) were coated 
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overnight at 4°C with whole RhCMV lysate (25µg/ml). Plasma samples were diluted at 
1:100. Anti-Rhesus IgG peroxidase-conjugated antibody was used to detect anti-RhCMV 
IgG (KPL, Gaithersburg, Md.). The specificity and reproducibility of the ELISA was 
confirmed using animal sera that were previously confirmed to be RhCMV positive and a 
plasma pool of seronegative animals. The limit of detection (LOD) was based on the average 
OD values plus 0.1 OD obtained for the plasma pool of RhCMV negative animals at the 
lowest dilution of 1:50. In addition, plasma samples were serially diluted after the initial rise 
in antibodies during the acute infection (week 10) and once during chronic infection when 
RhCMV-specific antibodies had stabilized. Antibody titers are reported as the lowest plasma 
dilution at which OD values were above the OD value for the RhCMV-negative plasma pool. 
RhCMV neutralizing antibodies (nAb) were determined as described previously (85), 
(2), (1). The following time points were used to cover the induction, rise and persistence of 
nAb: weeks 0, 6, 10, 16 and 40. Plasma from seronegative animals served as negative control. 
Data are reported as the reciprocal of the dilution that resulted in 50% neutralization (NT50). 
RhCMV quantitation 
RhCMV was quantitated in blood and bodily fluids as previously described (59, 131). 
DNA was extracted from plasma and saliva using the DNEasy Blood and Tissue Kit 
according to the manufacturer’s instructions (Qiagen, Valencia, CA). DNA from urine was 
extracted using the Norgen DNA Urine Isolation Kit (Norgen Biotech, Canada). 
Subsequently, real-time PCR for RhCMV gB was performed using the following primer and 
probe pair: forward primer: 5’-TGC GTA CTA TGG AAG AGA CAA TGC-3’, reverse 
primer: 5’-ACA TCT GGC CGT TCA AAA AAA C-3’ (Invitrogen, Carlsbad, CA), and 
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probe (5’-3’) TET-CCA GAA GTT GCG CAT CCG CTT GT-TAMRA (Applied 
Biosystems, Carlsbad, CA).  Each PCR reaction was ran in duplicate. The same amount of 
input DNA was used for RhCMV amplification from PBMC samples (100ng). However, due 
to the low DNA yield in some bodily fluids, the input DNA amount varied between 40 to 100 
ng. RhCMV was quantitated based on a RhCMV gB plasmid standard curve spanning 100 to 
106 copies. The viral load was calculated as RhCMV gB copies per ml for bodily fluids. The 
limit of detection was 10 copies of RhCMV gB.  
Statistical Analysis 
Statistical analysis was carried out using GraphPad Prism (GraphPad Software, Inc., 
La Jolla, CA). Data between infant and adult animals were compared using the unpaired 
Student t-test. Data with P< 0.05 were considered to be significantly different between 
groups. 
RESULTS AND DISCUSSION 	  
To mimic oral HCMV infection in children, 4-week old infant (n=5) and 5-year old 
young adult SPF macaques were orally (via the buccal pouch) infected with a natural 
RhCMV isolate (1x 106 PFU / ml) using a blunted syringe, and followed for 1 year. All 
infants, but only 1 of 3 adult animals, seroconverted within 2-4 weeks (85), (163), (162) 
(Figure 1A). The 2 seronegative adults received a second RhCMV dose at week 16. One 
animal seroconverted within 4 weeks, the other animal remained seronegative for 8 weeks, 
but had RhCMV antibodies by week 12 after the 2nd infection (Figure 1A). The data suggest 
that infants compared to adults have enhanced susceptibility to oral RhCMV infection. In 
addition to binding antibodies, all animals developed RhCMV-specific neutralizing 
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antibodies (2), (1) (Figure 1B). Although two of the adults showed the highest 50% 
neutralization titers (NT50), no statistically significant differences in NT50 values were 
detected between infant and adult animals. As all infant and 2 adult animals seroconverted 
within 4 weeks of RhCMV infection, animal #A3 likely became naturally infected, because 
the adult animals were co-housed. Possible infection via the natural route as opposed to the 
experimental oral exposure may explain the high NT50 for animal #A3. Animals #A1 and 
#A2 had qPCR-detectable RhCMV DNA in saliva at a single time point (59, 131) (Table 1), 
but it could not be conclusively determined whether these animals were actively shedding 
and transmitted RhCMV to #A3, because the RhCMV copy number was below the cut-off 
value (10 copies/ml). Consistent with observations in human infant HCMV infection, infant 
macaques showed pronounced high titer RhCMV shedding in saliva and urine (5), (107), 
(143), (165) (Table 1).  
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Table 1: RhCMV detection. 
Weeks Post-
Infection -4 0 2 4 6 8 10 12 16 20 24 28 32 36 40 44 48 52 Compartment 
INFANTS - - - - - - - - - - - - - - - - - - Plasma 
I.1 - NS - - - - - - - - - - - - - - - +++ Saliva 
  NS NS NS NS NS NS NS NS NS ++ +++ NS + + NS NS NS NS Urine 
  
                  
  
  - - - - - - - - - - - - - - - - - - Plasma 
I.2 - NS - - +/- - - - - - - +/- - +/- +/- - +/- - Saliva 
  NS NS NS NS NS NS NS NS NS - - NS +++ NS NS NS NS NS Urine 
  
                  
  
  - - - +/-   +/- +/- - - - - - - - - - - - Plasma 
I.3 - - - - - - - - +++ +/- ++ +++ ++ ++ +/- ++ + +/- Saliva 
  NS NS NS NS NS NS NS NS NS NS NS NS - +++ NS NS NS NS Urine 
  
                  
  
  - - - - - - - - NT NT NT NT NT NT NT NT NT NT Plasma 
I.4 - - - - - - - +/- - + NS ++ + +/- + + +/- NS Saliva 
  NS NS NS NS NS +/- NS + + ++ ++ + +++ NS + NS +++ NS Urine 
  
                  
  
  - - - - - - - +/- NT NT NT NT NT NT NT NT NT NT Plasma 
I.5 - - + +/- ++ + ++ +/- +/- +/- + - +/- +/- - +/- NS NS Saliva 
  NS NS NS NS NS NS NS +/- - NS + + NS NS NS NS - NS Urine 
  
                  
  
ADULTS - - - - - - - - - - - - - - - - - - Plasma 
A.1 - - - - +/- - - - - - - - - - - - - - Saliva 
  - - NS NS NS NS NS NS NS - - NS NS NS - - NS NS Urine 
  
                  
  
  - - - - - - - - - - - - - -         Plasma 
A.2 - - - - - - - - +/- - - - - -         Saliva 
  - NS - - - - NS - NS - - NS NS NS         Urine 
  
                  
  
  - - - -   -   - - - - -             Plasma 
A.3 - - - -   -   - - - - -             Saliva 
  - - - -   -   - NS - NS NS             Urine 
 
NS = no sample available NT = not tested 
 
+/- >1, but less than 10 copies (LOD) 
 
- 
 
negative 
 
+ >10, but less than 10^4 
 
++ >10^4<10^5 
 
+++ >10^5 !  
Better control of virus shedding in adults could not be explained by antibody 
responses because binding and neutralizing titers did not differ between infant and adult 
animals and persisted in both groups throughout the study period. Around the time of 
seroconversion, all animals showed an increase in Ki67 positive cells within the total CD4+ 
and CD8+ T cell populations, with the frequencies of Ki67 positive CD8+ T cells being 
significantly higher in adults than in infants (data not shown). Analysis of antigen-specific T 
cells in longitudinally collected blood samples by intracellular cytokine staining (IL2, IFNγ, 
and TNFα) showed that all animals developed CD4+ and CD8+ T cell responses to RhCMV 
lysate, RhCMV pp65 and RhCMV IE1 (Figure 1C) (2), (1), (91). There were no differences, 
however, in the magnitude, persistence, or quality of infant and adult T cell responses. 
	  	   72	  
Generally, RhCMV-specific T cells produced only a single cytokine, IFNγ or TNFα.  Dual-
positive cytokine responses were detected in 4 of 5 infant and 2 of 3 adult animals within the 
CD4+, and in 4 of 5 infants and 1 of 3 adult animals within the CD8+ T cell population (data 
not shown). These results are in contrast to the age-dependent increase in HCMV-specific T 
cells and to a similar age-dependency of RhCMV-specific T cell responses in non-SPF 
macaques (own unpublished data) (29), (143). As 5 year-old macaques are comparable to 15 
to 19 year old human teenagers, the age difference between the two animal groups in the 
current study might have been too small. Alternatively, the SPF status could have affected 
immune responsiveness. 
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Figure 1: Immune responses to oral RhCMV infection. A. RhCMV-specific antibody 
development. OD values for RhCMV-specific binding antibodies in longitudinally collected 
plasma samples (1:100 dilution). Infant animals are depicted in grey symbols and lines and 
adult animals in black symbols and lines. Arrows below the x-axis indicate the times of oral 
RhCMV exposure. The weeks post infection for all animals are based on the first oral 
RhCMV exposure at week 0. The dashed line shows the threshold for a sample to be 
considered RhCMV antibody positive based on the analysis of a pool of plasma collected 
from RhCMV-negative animals. B. Neutralizing antibody titers. Neutralizing antibodies for 
RhCMV were determined at weeks 0, 6, 10, 16 and 40 post RhCMV infection. Note that for 
animal A.3 only samples from weeks 0, 7, 14 and 22 were available. Shown are the NT50 
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titers for individual infant and adult macaques. C. RhCMV-specific T cell responses in 
peripheral blood. Shown are the total frequencies of single cytokine positive cells determined 
by Boolean gating analysis within the CD8+ T cell populations in individual animals. The 
sum of cytokine positive cells specific for RhCMV pp65 (black bars), RhCMV IE1 (white 
bars) and RhCMV lysate (striped bars) are shown at individual time points post RhCMV 
infection. Animal numbers are indicated on top of each graph. 
 
In this proof-of-concept study, we established an oral RhCMV infection model in 
infant SPF rhesus macaques. The findings can be summarized as follows:  (i) The 
susceptibility to oral RhCMV infection appears to decline with age, as 2 of 3 older animals 
required multiple oral RhCMV exposures to become infected, although this route proved to 
be 100% effective in infants. Future studies should determine host factors enhancing 
susceptibility to RhCMV infection within the oral microenvironment. (ii) Similar to HCMV 
infection in humans, infant macaques shed RhCMV more persistently and at higher titers 
compared to adult macaques. Viral shedding in saliva and urine might represent the most 
reliable marker to assess control of CMV infection, and efficacy of drug treatments and 
vaccines. (iii) Larger animal studies are needed to define immune parameters associated with 
better control of RhCMV in adult compared to young animals. In the limited study here, 
differences in the magnitude or quality of RhCMV-specific T and B cell responses could not 
be detected. However, this was the first time SPF animals were available, and as the SPF 
colony ages, more detailed virological and immunological studies, including tissue analysis, 
could be performed with larger animals groups. 
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CHAPTER 4: ALTERED CYTOKINE SIGNALING IN INFANT CD4+ T CELLS 	  
OVERVIEW  
CD4+ Th1 and Th2 cells elicit their function by producing distinct pattern of 
cytokines effective for intracellular pathogens and parasitic expulsion, respectively. CD4+ T 
cell differentiation is dependent on the infecting pathogen and the cytokine milieu generated 
by responding immune cells. A preferential CD4+ Th2 response is generated in the infant and 
Th1 in the adult against infectious diseases caused by intracellular pathogens. Such bias 
make infants, regardless of gestation, more susceptible to infectious diseases and experience 
greater morbidity and mortality compared to adults. Since infant CD4+ T cells are thought to 
be Th2-biased, we asked whether infant CD4+ T cells can respond to exogenous IFNγ. Our 
study tests the hypothesis that the propensity towards Th2 responses in infants is due to 
diminished cytokine-receptor mediated signaling in CD4+ Th1 cell differentiation. We also 
tested whether IL4 and IL2 cytokine signaling pathways are affected by gestational age. Our 
data showed that CD4+ T cells from cord blood of preterm (PT) and full term (FT) infants 
differ in Th1 and Th2-associated cytokine receptor expression from adult CD4+ T cells. 
Moreover, in vitro stimulation of whole blood with cytokines resulted in lower 
phosphorylation of JAK2 and STAT1 in FT infants compared to adult CD4+ T cells after 
IFNγ treatment. Moreover, purified CD4+ T cells from FT infants showed differential up-
regulation of IFNγ-induced genes after TCR and IFNγ stimulations. This treatment also 
resulted in generally higher cytokine production from adult compared to FT infant CD4+ T 
cells. A better understanding of the role of cytokine signaling in immune development is 
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important to delineate whether inefficient cytokine-receptor binding and downstream 
signaling components contribute to the immature status and impaired function of infant CD4+ 
T cells. Unraveling the molecular mechanisms involved may aid in pediatric vaccine designs.  
 
INTRODUCTION 
Cytokines present in the local environment are central in differentiation and 
commitment of CD4+ T cells into T helper 1 (Th1) or T helper 2 (Th2) lineages. Both IFNγ 
and IL12 are important for Th1 differentiation while IL4 is needed for Th2. Th1 cells secrete 
the cytokines IFNγ and IL2 to mediate protection against intracellular bacteria and viruses, 
whereas Th2 cells mainly produce IL4 and facilitate allergic inflammation and parasite 
expulsions (166), (167). Cytokines elicit their cellular actions by binding to specific receptors 
expressed on the cell’s membrane. Cytokine-receptor interaction results in the 
phosphorylation of receptor-associated Janus kinase (JAKs) family members (JAK1, 2, 3 and 
TYK2) (133), (58), (49, 103). The signal is then amplified and transduced by 
phosphorylating cytokine-specific transcription factors, the signal transducer and activators 
of transcription (STATs) (STAT1, 2, 3, 4, 5ab and 6). The transcription factors translocate to 
the nucleus where they regulate cytokine-specific gene expression. Cytokines and their 
respective transcription factor networks are critical in the establishment of the differentiated 
CD4+ T helper cell’s functional identity.  
Numerous research studies have been conducted to understand the unique status of 
the infant immune system. The results demonstrated that infant and adult CD4+ T cells have 
distinctive capacities to produce cytokines such as IFNγ, IL2 or IL4 (4), (3), (164), (31), (55).  
One particular feature that stands out is that infants and young children have a reduced ability 
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to produce the Th1-related cytokine, IFNγ. Moreover, studies showed the infant’s immune 
response to recall antigens selectively induces the death of Th1 cells by apoptosis, while 
concurrently, Th2-asssociated cytokine receptors were expressed at higher levels (88) (78). 
Interestingly, little is known about the responsiveness of infant CD4+ T cells to IFNγ or IL4. 
Specifically, we sought to determine whether the signaling machinery via the JAK/STAT 
pathway is operational in infant CD4+ T cells when exogenous IFNγ, IL4 or the T-cell 
growth factor, IL2, are provided. Not only are these three cytokines involved in CD4+ T cell 
differentiation, they are important for growth, maintenance and function of the distinct 
effector T helper subsets. Thus, we hypothesized that the preferential development of Th2 
response in infants is due to decreased activation of the components of the JAK/STAT 
signaling machinery needed for commitment towards Th1 development. 
Our results show that that the activation of different components of the cytokine-
receptor signaling pathway associated with Th1 development was reduced in infant 
compared to adult CD4+ T cells. Specifically, we found differences in IFNγ, IL4 and IL2 
signaling between infants and adults. Moreover, gestational age at birth (preterm (PT) vs. full 
term (FT) infants) was associated with unique signaling properties, and we observed an age-
dependent increase in activation of cytokine signaling factors in infants from birth to 1 year 
of age. Our results showed that the percentage of CD4+ T cells expressing IFNγR1 was 
significantly lower at birth compared to adult CD4+ T cells. However, on a per cell basis, 
infant CD4+ T cells at birth expressed more IFNγR1 than adult CD4+ T cells.  In contrast, 
frequencies of IFNγR2 positive CD4+ T cells and the expression of IFNγR2 on CD4+ T cells 
did not differ between infant and adult CD4+ T cells. Furthermore, both JAK2 and STAT1 
activation in response to IFNγ were reduced in CD4+ T cells at birth compared to adults but 
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responsiveness increased throughout the first year of life. In contrast to IFNγ, IL4 signaling 
in infant CD4+ T cells at birth was comparable to that observed in adult CD4+ T cells. In fact, 
both the percentage of CD4+ T cells expressing IL4Rα and the number of IL4Rα receptors on 
a per cell basis was higher in infants than in adults. Although STAT6 phosphorylation in 
response to IL4 was reduced in CB CD4+ T cells of PT and FT infant, by 2-5 months of age, 
STAT6 phosphorylation was as effective as in adult CD4+ T cells. Surprisingly, frequencies 
of IL2Rα positive CD4+ T cells were significantly lower in infants at birth, and were still 
significantly lower compared to adults at 1 year of age. However, the absolute number of 
IL2Rα receptors per CD4+ T cell was higher in infant compared to adult CD4+ T cells. 
Similar to the activation of the IFNγ signaling pathway in infant CD4+ T cells, STAT5 
phosphorylation in response to IL2 was reduced in infant CD4+ T cells at birth compared to 
adult CD4+ T cells, but increased throughout the first year of life. Differences in the 
activation of various components in cytokine signaling pathways were not only observed 
between the total CD4+ T cell populations of infants and adults, but these age-dependent 
differences were also observed within the naïve-T(N), central memory-T(CM) and 
effector/effector memory-T(E/EM) CD4+ T cell subsets. Lastly, in vitro stimulation through 
the TCR and exogenous addition of IFNγ revealed that FT infant and adult CD4+ T cells 
showed differences in the induction of genes encoding IFNγ, IL2, CXCL9 and other genes 
related to JAK/STAT signaling pathway. At the protein level, infant CD4+ T cells, in general, 
produced lower amounts of cytokines and chemokines compared to adult CD4+ T cells after 
stimulation through TCR only and in combination with exogenous IFNγ. Together, our data 
revealed that cytokine signaling is developmentally controlled as responsiveness to cytokines 
by infant CD4+ T cells increased with age. Such progression is likely associated with 
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immune maturation and antigen exposure. Our findings may shed light on possible molecular 
mechanisms that are the basis for the unique status of the infant immune system and offer 
insights in the design of pediatric vaccines and interventions.  
MATERIALS AND METHODS 
Human subjects 
All study populations were recruited from the University of North Carolina, Chapel 
Hill. Cord blood samples from full term (FT) infants collected with citrate-phosphate-
dextrose (CPD) anticoagulant were acquired either directly at delivery at the University of 
North Carolina Chapel Hill (UNC-CH) hospital with prior approval from the patient and/or 
requested from the Carolinas Cord Blood Bank (Duke Medicine, NC). Cord blood samples 
from preterm (PT) infants were collected in Ethylenediaminetetraacetic acid (EDTA)-
containing blood tubes. EDTA blood samples from older infants (2-12+ months [Mo.]) were 
obtained during routine doctor visits after obtaining signed consent (IRB protocol 11-1906, 
UNC Chapel Hill). Adult EDTA-blood samples were collected after written informed 
consent obtained from healthy blood donors of the UNC Center for AIDS Research 
Immunology Core Laboratory study (IRB protocol# 96-0859, UNC Chapel Hill).  
Sample processing 
Whole blood was used for JAK and STAT experiments. For all other assays, 
peripheral blood mononuclear cells (PBMC) were used. PBMCs were isolated by density 
gradient centrifugation using Lymphocyte Separation Medium (LSM, MP Biomedicals, OH). 
PBMCs were resuspended in serum free media (AIM V, GIBCO-Life Technologies, NY) 
supplemented with L-glutamine-penicillin-streptomycin antibiotic cocktail (Sigma, St Louis 
MO) at a concentration of 2x106 cells/ml. Cells were used for surface and cytokine receptor 
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quantification and for CD4+ T cell purification for gene and protein expression experiments.  
Flow cytometric analysis 
To determine T cell maturation, PBMCs were stained with the following antibody 
combinations: CD3 (SP34-2)-Pacific Blue, CD4 (L200)-PerCPCy5.5, CD8 (RPA-T8)-Alexa 
Fluor700, CD20 (2H7)-APC-H7, CD45RA (5H9)-FITC, and CCR7 (3D12)-PeCy7. The 
cytokine receptor expression on the surface of T cells was measured by staining with these T 
cell specific antibodies at 4°C in combination with the relevant cytokine receptor antibody 
(all in PE): IFNγR1 (CD119-GIR-208), IFNγR2 (2HUB-159, Biolegend, San Diego, CA), 
IL4Rα (hIL4R-M57), IL2Rα (CD25-clone-4E3, Miltenyi Biotec, Auburn, CA), or 
IL2Rβ (CD122-clone-Mikβ1). All antibodies, unless indicated otherwise, were purchased 
from BD Biosciences (San Diego, CA). The CD4+ T cell subsets are abbreviated and defined 
as follows: T(N)= Naïve ( CD45RA+/CCR7+); T(CM)= Central memory (CD45RA-
/CCR7+); and T(E/EM)= Effector/effector memory (CD45RA+/-/CCR7-). Cytokine receptor 
expression is reported as percentage of CD4+ T cell subpopulations or quantitated on a per 
cell basis using a linear equation based on a standard curve generated with Quantibrite PE 
beads (BD Biosciences).  
Phosflow Analysis 
Activation of JAK2 and STAT molecules was measured by Phosflow analysis. 
Briefly, JAK2 activation was measured after whole blood was stimulated for 10 min with 
10µg/ml of human recombinant IFNγ1b (Miltenyi Biotec, Auburn, CA). STAT 
phosphorylation was measured after activation of whole blood for 15 min with either 
10µg/ml of human recombinant IFNγ1b, 0.1µg/ml of recombinant rhesus IL4 (R&D, 
Minneapolis, MN) or 0.1µg/ml of recombinant human IL2 (Miltenyi Biotec, Auburn CA). 
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Note: Recombinant human and rhesus IL4 were tested separately and yielded comparable 
results (data not shown). The following antibodies were used to identity CD4+ T cells and 
maturity status: CD3 (SP34-2)-PeCy7, CD4 (L200)-PerCPCy5.5, CD27 (L128)-PE and 
STAT1 (pY701)-Alexa Fluor488 (Cell Signaling Technology, Danvers MA) or STAT6 
(pY641)- Alexa Fluor488, or STAT5 (pY694)- Alexa Fluor647 to determine STAT 
phosphorylation after IFNγ, IL4 or IL2 treatment, respectively or JAK2 (D4A8-Tyr1008)-
Alexa647 (Cell Signaling Technology, Danvers MA) phosphorylation after IFNγ treatment. 
The CD4+ T cell subsets were also abbreviated and defined as follows: T(N)= naïve (CD27+); 
T(CM)= Central memory (CD27low); and T(E/EM)= Effector/effector memory (CD27-) 
Unstimulated whole blood served as negative controls. The flow cytometric staining 
procedures were adapted according to BD Phosflow protocols with the following buffers: 
Lyse/fix, Perm Buffer III, and Phosflow buffer (PBS +2% heat-inactivated FBS +0.09% 
Sodium Azide). Cells positive for JAK2 or STAT phosphorylation are reported as percentage 
of CD4+ T cells after subtraction of values from negative controls (unstimulated sample).  
 
All flow cytometric samples were acquired on a LSRII flow cytometer (BD 
Biosciences, San Jose, CA). A minimum of 300,000 events was acquired for both receptor 
expression and phosphorylation. Data were analyzed using FlowJo Software (Tree Star, 
Ashland, Oregon). Antibodies were titrated prior to use and gates for certain cell populations 
were based on FMO controls.  
 
CD4+ T cell enrichment/purification 
CD4+ T cells were purified from both cord and adult blood using the Stem Cell CD4+ 
Enrichment kit, according to the manufacturer’s protocols (STEMCELL Technology, 
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Vancouver, Canada). Purity of CD4+ T cells was confirmed by flow cytometry and purity 
exceeded 97%. Cells were cultured at a concentration of 2x106 /ml under the following 
conditions: 1) unstimulated (Aim V media), 2) T cell receptor (TCR) stimulation using 1µg 
of anti-CD3 (UCHT1) and anti-CD28 (L293) antibodies, and 3) a combination of TCR (anti-
CD3 and anti-CD28) stimulation plus 10µg/ml of human recombinant IFNγ1b added at the 
start of culture. TCR stimulation was prepared by first coating 96-well round bottom plates 
overnight with 1µg of pure anti-CD3 and anti-CD28 antibodies per well. Unbound antibodies 
were removed by washing 3x with sterile PBS. A total of 10 wells/condition received 
200,000 cells/well and cells were incubated at 37°C, 5% CO2 for 24 h. The 10 wells from 
each condition were harvested and the supernatants were stored at -800C for  cytokine 
analysis by Luminex Technology and cells were used for PCR array. 
Profiling of multiple cytokines and chemokines using a Luminex® –based assay 
Supernatants from the 3 conditions described above were tested for cytokine 
production using the Milliplex Mag Human Cytokine/Chemokine Panel containing 20 
analytes (IFNγ, IL10, IL5, IL17A, IL1α, IL1β, IL9, IL2, IL6, IL7, IL8, TNFα, TGFα, GM-
CSF, IL12p70, PDGF-AA, IP10, MCP1, MIP1α, and MIP1β). All procedures were 
performed as described in the manufacturer’s protocol and were acquired on a Luminex 
xMAP® MagPix platform (EMD Millipore, MA). 
Real time RT-PCR analysis of JAK-STAT signaling 
RNA was isolated from cells under the 3 conditions described above using the Qiagen 
RNEasy Mini Kit (Qiagen, Germany). DNase treatment with RNAse-Free DNAse Set 
(Qiagen) was performed to eliminate genomic DNA contamination. RNA was reverse 
transcribed using the RT2 First Strand kit (Qiagen) and cDNA was subsequently amplified 
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using the RT2 JAKSTAT Signaling Pathways PCR Array. PCR was performed according to 
the manufacturer’s protocol. Data analysis was performed using the web-based software for 
PCR arrays on the SA Bioscience website (http://www.sabiosciences.com/dataanalysis.php) 
Statistical Analysis 
Receptor expression and JAK/STAT phosphorylation results are expressed as median 
values. All graphs and analyses were performed using GraphPad Prism for Mac Version 5.0. 
Significant differences between multiple groups were determined by Kruskal-Wallis test 
followed by Dunn’s Multiple Comparison test. P values of p<0.05 were considered 
significant.  
RESULTS 	  
Expression of Th1-associated receptors, kinase and cytoplasmic transcription factor is age-
dependent 
 
In order for cytokines to exert their functions, they must bind to their respective 
receptors, activate their associated JAKs and respective STAT molecules. The magnitude and 
kinetics of the cell’s response might depend on the number of receptors present on the cell 
surface and the availability of the signaling components downstream. We first assessed both 
the frequency and absolute number of receptors related to Th1 or Th2 responses on resting 
CD4+ T cells. Our data show that infants have altered expression of both Th1 and Th2 
cytokine- related receptors. Specifically, the frequency of IFNγR1-expressing CD4+ T cells 
was higher in adults compared to CB (PT or FT infants) CD4+ T cells regardless of the 
gestational age of the infant (Figure 1). Even infants between 2-12+ months of age had lower 
frequencies of IFNγR1-expressing CD4+ T cells than adults. Considering the distinct cell 
differentiation of infant and adult CD4+ T cells, with infant blood containing predominantly 
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T(N) CD4+ T cells, we deemed it important to confirm these findings in differentiated CD4+ 
T cells. Surprisingly, we observed lower frequencies of IFNγR1+ CD4+ T cells in adults 
compared to PT and FT infants at birth when we specifically analyzed T(N) CD4+ T cells 
while the adults contained higher frequencies of IFNγR1+ T(E/EM) CD4+ T cells. We could 
not detect statistical differences within the T(CM) CD4+ T cells (Figure 1A-D, left). 
Intriguingly, IFNγR1 expression was mainly confined to the T(E/EM) compartment. 
However, when we compared absolute numbers of IFNγR1 on a per cell basis, we observed 
that CD4+ T cells at birth had significantly higher numbers of IFNγR1 per cell compared to 
adults across all subsets (Figure 1E-H, right panel). The age-related differences in receptor 
numbers were irrespective of gestational age as both PT and FT infants at birth had higher 
numbers of IFNγR1 on a per cell basis, and this was true for all CD4+ T cell subsets. As the 
IFNγ receptor exists as a heterodimer, we also assessed the expression of the signaling chain, 
IFNγR2.  Although we observed higher frequencies of IFNγR2 –expressing T(N) and 
T(E/EM) CD4+ T cells in adults, (Figure 2A-D), absolute numbers of IFNγR2 on a per cell 
basis did not differ between the various age groups. (Figure 2E-H).  
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Figure 1: Frequencies and absolute numbers of IFNγR1 on CD4+ T cell subsets. Panels 
A-D show the frequencies of IFNγR1- expressing CD4+ T cells. Panels E-H show the 
absolute number of IFNγR1 per CD4+ T cell. Each symbol represents an individual. Red 
circles represent adults and colored triangles represent different infant age groups. Peripheral 
blood mononuclear cells from preterm (PT, n=18, light blue), full term (FT, n=24, blue), 2-5 
Mo. (n=4, light green), 8 Mo. (n=2, dark yellow), 12+ Mo. old infants (n=7, green), and 
adults (n=29, red circles) were isolated and stained for flow cytometric analysis. Horizontal 
lines represent median values. Statistical differences among all groups were determined by 
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Kruskal-Wallis test and the P- value is listed in the top left corner. Capped lines show 
statistical significant differences between two groups as determined by Dunn’s comparison 
test.  
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Figure 2: Frequencies and absolute numbers of IFNγR2 on CD4+ T cell subsets. The 
legend is as described in Figure 1 with the following sample numbers: PT, n=18; FT, n= 25; 
2-5 Mo., n= 4, 8 Mo., n=1, 12+ Mo., n=7; and adults, n=25.  
Since cytokine receptors lack intrinsic kinase activity, we next determined if the 
activation of relevant receptor-associated JAKs and corresponding STAT molecules differed 
between the various age groups. As our main focus was on the evaluation of IFNγ responses 
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in infants, we focused on the evaluation of JAK2 activation in response to IFNγ treatment in 
FT infants at birth, 12+ month old infants and adults.  We found that the phosphorylation of 
JAK2 (pJAK2) in response to IFNγ in T(N) CD4+ T cells of FT infants was significantly 
lower compared to adults (Figure 3A-B). Though not statistically significant, it appeared that 
adult T(CM) had higher frequencies of CD4+ T cells expressing activated JAK2 than FT 
infants at birth. There was no difference in JAK2 phosphorylation in the T(E/EM) 
compartment (Figure 3C-D). Moreover, there was a significant increase of pJAK2 in 12+ 
month old infants compared to FT infants in the both T(N) and T(CM) compartments except 
in the T(E/EM) (Figure 3A-C). Interestingly, 12+ month old infants also have higher 
frequencies of pJAK2 compared to adults both within the T(CM) and T(E/EM) 
compartments (Figure 3C-D). Consistent with lower JAK2 activation, STAT1 
phosphorylation (pSTAT1) in CD4+ T cells after IFNγ treatment was also significantly lower 
in FT infants compared to adults in all CD4+ T cell subsets except in the TE/EM 
compartment (Figure 4A-C). Surprisingly, PT infants seemed to respond to IFNγ treatment 
better than FT infants as higher pSTAT1 was observed in both T(N) and T(CM) 
compartments (Figure 4B&C). Additionally, CD4+ T cells from FT infants at birth had 
considerably lower pSTAT1 expression compared to older infants that were 2-5 months and 
12+ months, consistent with lower JAK2 phosphorylation. There appeared to be an age-
dependent increase of IFNγ responsiveness assessed by STAT1 phosphorylation reflected in 
all CD4+ T cell subsets (Figure 4A-D).  
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Figure 3: JAK2 phosphorylation (pJAK2) after IFNγ stimulation is increased with age. 
Shown are percentages of pJAK2 positive cells within the A. Total CD4+ T cell population, B. 
T(N) CD4+ T cells. C. T(CM) CD4+ T cells  and D. T(E/EM) CD4+ T cells. Each symbol 
represents an individual. Red circles represent adults and colored triangles represent different 
infant age groups. Whole blood from full term (FT, n=7, blue), 12+ Mo. old infants (5, 
green), and Adults (11, red circles) were treated with or without recombinant human IFNγ 
(10µg/ml) for 10 min, fixed, permeabilized and stained for Phosflow. Statistical differences 
among all groups were determined by Kruskal-Wallis test and the P- value is listed in the top 
left corner. Horizontal lines represent median values. Capped lines show statistical 
significant differences between two groups as determined by Dunn’s comparison test.  
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Figure 4: STAT1 phosphorylation (pSTAT1) is increased with age. Shown are 
percentages of STAT1 positive cells within the A. Total CD4+ T cell population, B. T(N) 
CD4+ T cells. C. T(CM) CD4+ T cells  and D. T(E/EM) CD4+ T cells. Each symbol 
represents an individual. Red circles represent adults and colored triangles represent different 
infant age groups. Whole blood from preterm (PT, n=13, light blue), full term (FT, n=38, 
blue), 2-5 Mo. (n=4, light green), 12+ Mo. old infants (n=10, green), and Adults (n=22, red 
circles) were treated with or without recombinant human IFNγ (10µg/ml) for 15 min, fixed, 
permeabilized and stained for Phosflow. Statistical differences among all groups were 
determined by Kruskal-Wallis test and the P- value is listed in the top left corner. Horizontal 
lines represent median values. Capped lines show statistical significant differences between 
two groups as determined by Dunn’s comparison test.  
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Propensity of infant compared to adult CD4+ T cells to express Th2-associated receptors 
and cytoplasmic transcription factors  
 
Given that infants have a Th2-biases response, we tested whether infant CD4+ T cells 
preferentially express Th2-associated cytokine receptors (IL4Rα) and respond to the 
canonical Th2 cytokine, IL4, via the phosphorylation of the cytoplasmic transcription factor, 
STAT6 similar to adult CD4+ T cells. In general, we found that the frequencies of CD4+ T 
cells positive for the IL4Rα were not significantly different between CB (PT & FT), older 
infants or adults (Figure 5A). Although the frequencies of IL4Rα expressing T(N) CD4+ T 
cells differed significantly among all groups by Kruskal-Wallis analysis, only TCM and not 
T(E/EM) from FT and PT infants at birth contained higher frequencies of IL4Rα positive 
cells than adults (Figure 5B-D). Assessing the number of receptors on a per cell basis, both 
PT and FT infants had significantly more IL4Rα per CD4+ T cell within both T(N) and T 
(E/EM) compartments while only PT and adults were different in the T(CM) (Figure 5E-H).  
Interestingly, we also observed that within T(E/EM) compartment, FT infants had higher 
IL4Rα numbers than 12+ month old infants (Figure 5H). To determine whether cytokine 
receptor expression could influence the Th2-bias, we compared the ratio of IL4Rα:IFNγR2 
on CD4+ T cells. Although we had access to only few blood samples between birth and 1 
year of age, the ratios of IL4Rα and IFNγR2 within the different compartments were 
statistically different across the various age groups (Figure 6A-D). Specifically, we found 
that FT infants at birth compared to 2-5 month olds and to adults, showed a bias towards 
higher IL4Rα expression as opposed to IFNγR2 expression within the T(N) compartment 
(Figure 6B).  
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Figure 5: Frequencies and absolute numbers of IL4Rα on CD4+ T cell subsets. The 
legend is as described in Figure 1 with the following sample numbers: PT, n=20; FT, n=24; 
2-5 Mo., n=4; 8 Mo., n=2; 12+ Mo, n=7; and adults, n=25.  
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Figure 6: The ratio of IL4Rα/IFNγR2 within CD4+ T cells and subsets shows a Th2-bias. 
Shown are the ratio of receptors within the A. Total CD4+ T cell population, B. T(N) CD4+ T 
cells, C. T(CM) CD4+ T cells, D. T(E/EM) CD4+ T cells of (PT, n=15; FT, n=21; 2-5 Mo., 
n=4; 8 Mo., n=1; 12+ Mo., n=7, green; and adults, n=20. Statistical analysis and labels are as 
described in Figure 1.  
In contrast to IFNγ stimulation, a much higher percentage of infant CD4+ T cells 
seemed to have the ability to respond to IL4, as assessed by STAT6 phosphorylation 
(pSTAT6) (Figure 7A-D). However, the responses of FT infant CD4+ T cells at birth showed 
significantly less pSTAT6 compared to adults and older infants that were 12+ Mo. of age. 
Analogous results were also detected in the T(N) and memory subsets (T(CM) and T(E/EM)) 
of CD4+ T cells (Figure 7B-D). Furthermore, gestational age didn't seem to make a difference 
in affecting the ability of PT or FT infant CD4+ T cells to respond to IL4. A higher 
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percentage of CD4+ T cells at birth was able to respond to IL4 not IFNγ, as both the 
percentage of IL4Rα-expressing CD4+ T cells and the number of the IL4Rα on a per cell 
basis were higher in the infants compared to adults. Thus, these data revealed that infants 
readily responded to IL4 at birth and continuing on, at least in the first year of life, showing 
the propensity of infant CD4+ T cells to develop towards Th2.  
! 
Figure 7: Detection of STAT6 phosphorylation (pSTAT6) at birth. Shown are 
percentages of STAT6 positive cells within the A. Total CD4+ T cell population, B. T(N) 
CD4+ T cells. C. T(CM) CD4+ T cells and D. T(E/EM) CD4+ T cells of PT, n=12; FT, n=38; 
2-5 Mo., n=3; 12+ Mo., n=7; and adults, n=26. Whole blood from these samples were treated 
with or without recombinant rhesus IL4 (0.1µg/ml) for 15 min, fixed, permeabilized and 
stained for Phosflow. Statistical analysis, legends and other labels are as described in Figure 
4.  
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Responsiveness to IL2 is age-dependent 
Interleukin 2 is a growth factor required for the differentiation and expansion of both 
Th1 and Th2 cells. We sought to determine whether the deficiency to develop adequate Th1 
responses might also be due to the reduced ability of infant CD4+ T cells to respond to IL2. 
We evaluated 2 of the 3 subunits of the IL2 receptor complex, α and β chains, respectively 
corresponding to the binding and signaling chains. We found that the frequency of 
IL2Rα-expressing CD4+ T cells was significantly higher in the adults compared to FT infants 
at birth (Figure 8A). Interestingly, CD4+ T cells at birth from PT infants had even higher 
frequencies of IL2Rα-expressing CD4+ T cells than FT infants (Figure 8A-D). Furthermore, 
there was a significant difference in IL2Rα expression in PT infants at birth and adult CD4+ 
T cells within the T(CM) but not in the T(N) and T(E/EM) compartments. Based on the 
number of receptors on the CD4+ T cell surface, we observed significantly higher numbers of 
IL2Rα in T(N) and T (CM) CD4+ T cells at birth of PT infants compared to adults (Figure 
8F&G) whereas, only within the T(E/EM) compartment that we observed higher numbers of 
IL2Rα in FT infants compared to adults (Figure 8H). Interestingly, infants that were 2-5 
months of age had significantly more IL2Rα compared to adults in T(N) and T(CM) 
compartments. The frequency T(N) CD4+ T cells expressing the signaling chain, IL2Rβ, in 
the PT infants appeared higher than in adults (Figure 9B). However, the absolute number of 
IL2Rβ on a per cell basis was not significantly different across the different age groups 
(Figure 9E-H).  
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Figure 8: Frequencies and absolute numbers of IL2Rα on CD4+ T cell subsets. The 
legend is as described in Figure 1 with the following sample numbers: PT, n=16; FT, n=21; 
2-5 Mo., n=3; 8 Mo., n=1; 12+ Mo., n=6; and adults, n=12 were isolated and stained for flow 
cytometric analysis.  
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Figure 9: Frequencies and absolute numbers of IL2Rβ on CD4+ T cell subsets. The 
legend is as described in Figure 1 with the following sample numbers: PT, n=16; FT, n=20; 
2-5 Mo., n=2; 8 Mo., n=1; 12+ Mo., n=4; and adults, n=12 were isolated and stained for flow 
cytometric analysis.  
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Unexpectedly, infants at birth (CB) had a significantly lower ability to phosphorylate 
STAT5 (pSTAT5) in response to IL2 even though infants had more IL2Rα on the cell surface 
and similar frequencies of IL12Rβ positive CD4+ T cells and similar numbers of IL2Rβ per 
CD4+ T cell. In particular, both PT and FT infants at birth had significantly lower pSTAT5 
compared to adults in total CD4+ T cells and within the different CD4+ T cell subsets (Figure 
10-A-D). Moreover, we found that STAT5 activation across the different subsets was 
significantly higher in 12+ month old infants compared to FT infants at birth. Similar to IFNγ 
responses, the ability to respond to IL2 seemed to increase with age as 2-5 month old infants 
started to gain the ability to respond to IL2. Although not statistically significant, even at 12+ 
months of age, infant CD4+ T cells still showed a trend towards lower ability to activate 
STAT5 compared to adult CD4+ T cells. Together with our receptor data, our findings 
indicated differential activation of the IL2 associated transcription factor STAT5 on infants 
and adult CD4+ T cells and subsets, suggesting a correlation of CD4+ T cell maturity and age. 
The decreased ability to respond to a potent T cell growth factor may direct the infant’s 
immune responsiveness away from Th1.    
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Figure 10. STAT5 phosphorylation (pSTAT5) is increased with age. Shown are 
percentages of STAT5 positive cells within the A. Total CD4+ T cell population, B. T(N) 
CD4+ T cells. C. T(CM) CD4+ T cells and D. T(E/EM) CD4+ T cells of PT, n=13; FT, n=38; 
2-5 Mo., n=4; 12+ Mo., n=10; and adults, n=22. Whole blood from these samples were 
treated with or without recombinant human IL2 (0.1µg/ml) for 15 min, fixed, permeabilized 
and stained for Phosflow. Statistical analysis, legends and other labels are as describe in 
Figure 4. 
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Addition of exogenous IFNγ resulted in unique gene and protein expression between TCR 
stimulated infant and adult CD4+ T cells 
 
The combined effect of TCR and cytokines will result in the activation of various 
signaling pathways and transcription factor networks which will act in synergy to promote 
cellular differentiation and specialized patterns of gene expression in differentiated cells (8), 
(104). Thus, our last attempts to unravel the reasons for the diminished Th1 activity in infants 
were to determine the resulting gene and protein expression between infant and adult CD4+ T 
cells after in vitro stimulations. We activated CD4+ T cells from FT infants at birth and adults 
under 2 conditions: i) directly through the TCR only by using anti CD3 and CD28 antibodies 
and ii) a combination of stimulation through the TCR and exogenous IFNγ (added 
immediately at the start of culture). Our data showed that the combination of the stimuli 
seemed to have an additive effect, especially in the induction of genes encoding IFNγ, IL2 
and CXCL9. Notably, the combined stimulation induced a broad range of genes related to the 
JAK/STAT signaling pathway including STAT-induced genes and negative regulators 
(Figure 11). Moreover, genes involved in the immune response and cell growth/maintenance 
were also differentially expressed in FT infant and adult CD4+ T cells. Statistical analysis 
was not performed due to low numbers.  
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Figure 11. Infant and adult purified CD4+ T cells induced distinctive genes related to 
JAK/STAT signaling. Purified CD4+ T cells from full term (FT) and adults were stimulated 
through the TCR using plate bound anti CD3/28 only (FT n=2, light blue and adult n=1, light 
red) and TCR with exogenous recombinant human IFNγ (FT, n=3; dark blue or adults, n=2; 
dark red) and cultured for 24 hr. RNAs were extracted, processed and analyzed as described 
in Materials and Methods.  
Supernatants from TCR only and TCR+IFNγ stimulated infant and adult CD4+ T cell 
cultures were tested for a panel of cytokines and chemokines to determine changes in 
cytokine production. Infant CD4+ T cells generally produced lower amounts of cytokines 
than adults (Figure 12). Upon stimulation through the TCR only, every marker analyzed was 
expressed at lower levels in infant CD4+ T cell cultures compared to adults, except PDGF-
AA (Figure 12A-B). The addition of IFNγ to TCR stimulation resulted in the up-regulation 
of most cytokines and chemokines in the infant CD4+ T cell cultures compared to TCR only 
stimulation. The combined stimulation through the TCR and IFNγ overcame some 
differences in the production of certain cytokines or chemokines (e.g. IL8, IP-10) by infant 
and adult CD4+ T cells while others (e.g. IL15, TGFα) were still produced at lower levels 
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(Figure 12A&B). Moreover, the exogenous addition of IFNγ with TCR stimulation resulted 
in the up-regulation of some Th1 and Th2 –associated cytokines like IL2, and IL10, Th17-
associated cytokine IL17A, and pro-inflammatory cytokines such as TNFα, IL1α and IL1β. 
However, statistical analysis was not performed due to small number sizes and data on IFNγ 
only stimulations were not available for comparison. Our data did reveal that the combination 
of TCR and exogenous IFNγ stimuli on infant and adult CD4+ T cells resulted in a broad up-
regulation of distinctive genes and protein productions. The resulting cellular responses may 
have implications in the preferential development of certain CD4+ T helper cell subsets in 
infants.  
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Figure 12: Purified infant and adult CD4+ T cells induced a unique blend of cytokines 
and chemokines after in vitro stimulation. Purified CD4+ T cells from FT infants and 
adults were stimulated through the TCR using plate bound anti CD3/28 only (FT n=3, light 
blue and adults n=4, light red) and TCR with exogenous recombinant human IFNγ (FT, n=4; 
dark blue or adults, n=4; dark red) and cultured for 24 hr. Supernatants were assayed using 
Luminex technology to measure A. cytokines and B. Chemokines as described in Materials 
and Methods. 
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DISCUSSION 	  
In this study, we tested whether IFNγ, IL4 or IL2 -receptor mediated signaling 
through the JAK/STAT pathway could provide novel insights into the preferential Th2 
development and diminished Th1 response of infant CD4+ T cells. Reduced ability to 
respond to IFNγ, IL4, and IL2 may have broader impact as these cytokines and their 
respective transcriptional network are involved in epigenetic modifications affecting CD4+ T 
cell differentiation. We postulated that the preferential development of Th2 response in 
infants is due to reduced activation of the components of IFNγ-receptor mediated JAK/STAT 
signaling machinery to appropriately induce Th1 development. We have now shown that the 
diminished Th1 activity and Th2-biased in infants could be attributed to the differential 
processing of signals initiated by IFNγ and IL4. IL4 responsiveness and to a lesser degree 
IFNγ, was readily detected at birth. Additionally, our data on IL2 responsiveness indicated 
that infant CD4+ T cells have reduced ability to respond to a potent T cell growth factor, 
potentially affecting the expansion of naïve and differentiated CD4+ T cells. Approximately 
at 2-5 months of age, infants gained the ability to respond to both IFNγ and IL2. Our findings 
could be summarized as follows: 1) Cytokine signaling is reduced in infant compared to adult 
CD4+ T cells, 2) Altered cytokine signaling is due to multiple factors, including receptor 
expression, activation of kinases (JAKs) and phosphorylation of cytoplasmic transcription 
factors (STATs), 3) Gradual cytokine responsiveness is associated with age and 
differentiated status of CD4+ T cells, 4) Kinetics of cytokine responsiveness is cytokine 
specific and 5) Gestational age influences the ability of infant CD4+ T cells to respond to 
cytokines. Figure 13 schematically illustrates these findings.  
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Figure 13: Altered cytokine-receptor signaling in infant and adult CD4+ T cells affect 
the generation of Th1 immunity. A. The pool of infant CD4+ T cells predominantly consist 
of naïve T cells (T(N)) compared to higher presence of differentiated or memory (T(CM) and 
T(E/EM)) CD4+ T cells in B. adults . When cytokines like IFNγ (red circles) bind to 
receptors, infants CD4+ T cells have higher density of Th1-associated receptors (depicted as 
2 black lines) compared to adults but have reduced signaling capabilities (JAKs and STATs) 
(depicted as a lightning bolt). Together with the lower frequency of memory and 
differentiated CD4+ T cells, the net cytokine responsiveness in infants is weak compared to 
adults affecting the development of Th1. Gradual increase in cytokine responsiveness is 
associated with increasing age.  
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One caveat of our study was that frequencies and absolute number of receptors were 
assessed on resting CD4+ T cells. It is likely that Th1 or Th2-associated receptors will have 
differential kinetics under polarized conditions. Other studies had determined that IFNγR1 
expression and distribution is ubiquitous, but within T cells, IFNγ-STAT1 signaling is 
detected only in naïve and polarized Th2 cells as they express the signaling chain IFNγR2 
(120), (109). Moreover, Th1 cells do not express IFNγR2 due to reduced gene transcription 
but these cells can re-express IFNγR2 after TCR stimulation. Interestingly, there are also 
reports on IFNγ mediating the death or proliferation of T cells and other IFNγR2 expressing 
cells (17). Though expression of IFNγR2 may result in death of T cells, IFNγ derived from 
CD4+ T cells is sufficient to induce the development of Th1 cells (151). In our study, it was 
difficult to determine whether infant or adult CD4+ T cells and subsets lost IFNγR2 
expression as the receptor was immediately assayed after cell isolation. Additionally, our 
data are still incomplete, as we still need to show that PT and older infants have lower or 
higher JAK2 activation. Acquiring samples from these age groups and increasing our 
numbers are currently underway in the lab.   
Studies looking at cytokine signaling in other immune cells showed that neonatal 
macrophages (MΦ) had a deficient ability to respond to IFNγ (89). Their data were not 
attributed to the lower IFNγ receptor expression on MΦ, or total STAT 1 protein levels, but 
instead due to defective phosphorylation of STAT1. The reason of lower STAT1 
phosphorylation was not determined but our data suggested that a possible defect is upstream 
of STAT1. We found that JAK2, one of the JAK kinases associated with the IFNγ receptor 
complex, showed lower phosphorylation in CD4+ T cells of FT infants than adults. Our data 
showed that within 10 min and 15 min, lower activation of JAK2 and STAT1 by IFNγ 
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treatment, respectively, was observed in infants, demonstrating that though infants have the 
necessary receptors present on the CD4+ T cell surface or even higher compared to adults, the 
frequency of cells able to respond to IFNγ might not be sufficient to exhibit a detectable 
response. Indeed, infants compared to adults have much lower frequencies of differentiated 
CD4+ T cells (unpublished observations).  
We confirmed in our studies through IL4-signaling that infants preferentially develop 
a Th2-biased response. We have shown that the ratio between IL4Rα and IFNγR2 distinctly 
favored Th2 in infants. Moreover, after IL4 treatment, phosphorylation of downstream 
signaling component, STAT6, was readily detectable in PT and FT infants in all CD4+ T cell 
subsets, consistent with having higher numbers of IL4Rα per CD4+ T cell. Interestingly, 
research showed that IL4 receptor expression could be modulated by intracellular signaling 
pathways and by the cytokine itself at both the transcriptional and post-transcriptional level 
(40), (97). The propensity of infant CD4+ T cells to respond to IL4 by pSTAT6 supports their 
bias towards a Th2 response, as IFNγ treatment did not result in similarly high frequencies of 
pSTAT1 positive CD4+ T cells. However, STAT6 activation was highly variable with some 
FT infants having much lower responses compared to older infants and adults. There might 
be other underlying mechanisms controlling these variable responses in the FT infants at 
birth. Future experiments need to determine the relevant JAK kinase (JAK1) involved to 
completely define this IL4-STAT6 signaling axis in infants. We expect to find variable 
degrees of JAK1 phosphorylation after IL4 treatment in infant CD4+ T cells regardless of 
gestation.   
Observations in our lab showed that infant CD4+ T cells are able to produce IL2 and 
initial expansion was evident as assessed by Ki67 expression during the first weeks of life 
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(unpublished results). These observations suggested to us that infant CD4+ T cells should 
have similar IL2 responsiveness as adults. Thus, we wanted to determine the extent of IL2 
involvement in Th1 development. Unexpectedly, infant CD4+ T cells showed reduced 
responsiveness to IL2 compared to adults. We found that IL2Rα but not IL2Rβ expressing 
CD4+ T cells were higher in the adults compared to infants. However, infants had 
significantly higher absolute numbers of IL2Rα per cell, but no difference was observed in 
the IL2Rβ chain. When stimulated with IL2, infant CD4+ T cells showed drastically less 
STAT5 phosphorylation compared to adults. However, there was a trend of increasing IL2 
responsiveness because older infants had more pSTAT5 positive CD4+ T ells than FT infants. 
Research also showed that infants have a higher frequency of regulatory T cells and these 
cells are phenotypically recognized to express CD25high, or also known as IL2Rα (52), (160), 
(56). Early studies in the field also demonstrated that IL2 is a strong IFNγ-inducing cytokine 
in human T cells (69), (148). Our gene and protein expression data showed that after 
stimulation through the TCR and IFNγ, slightly higher expression of Il2ra gene and protein 
was observed in purified adult than in infant CD4+ T cells. Moreover, IL2 has a broader role 
in T helper differentiation as it has the ability to modulate expression of key cytokine 
receptors involved in both Th1 and Th2 specificity and maintenance (81), (80). Reduced 
responsiveness to both IL2 and IFNγ cytokines could result in an additive effect and may 
lead to the Th1 diminished response in infants.  
In conclusion, our findings have demonstrated a role of cytokine-receptor mediated 
signaling in infant immune development and maturation especially in the CD4+ T cell 
response. Nupponen et al had described multiple aberrations in signaling profiles in CB 
lymphocytes but cytokine signaling data in specific CD4+ T cell subsets in the developing 
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infant are still lacking (102). We showed that receptiveness of infant and adult CD4+ T cells 
and subsets to cytokines resulted in a distinct activation of the JAK/STAT signal transduction 
network. Such transduction networks act in synergy with other signals such as those 
experienced by naïve CD4+ T cells after encountering their cognate antigens. Differentiation 
of these cells to Th1 or Th2 will involved epigenetic changes at the chromatin level that may 
affect the Ifng, and Il4 locus making them accessible to number of Th1 or Th2 lineage-
specifying transcription factors (158), (12). The findings in our study provided additional 
molecular mechanisms that elucidated the unique immune status of infants, especially in 
regards to the altered function of infant CD4+ T cells. Delineating the immune mechanisms 
that control or modulate CD4+ T cell responsiveness and function in the unique infant 
environment will be important in both biological and immunological processes. Our findings 
may be of value in formulating pediatric vaccines and therapeutics that are protective early in 
life. 
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CHAPTER 5: SUMMARY, SIGNIFICANCE, FUTURE DIRECTIONS AND 
CONCLUSIONS 
 
SUMMARY OF FINDINGS 
  The research in our lab is centered on pediatric infectious diseases. Our goal is to 
determine why disease outcome is often more severe in infants compared to adults. During 
the window of time when passive immunity from the mother wanes and the infant’s immune 
cells and their functions still develop, infants are especially vulnerable to many diseases. My 
research project was aimed at defining the role of infant CD4+ T cells in viral pathogenesis. 
The infant immune system is generally described as being immature. I examined the term 
“immature” by assessing what functional properties of CD4+ T cells are different in infant 
and adults and determined whether differences in CD4+ T cells function could impact viral 
pathogenesis. Our primary question was: When do infant immune cells reach maturity and 
function equally well as adult cells? Toward this objective, I pursued several different 
projects covered in Chapters 2, 3 and 4.  
The study described in Chapter 2 was part of a larger collaborative effort to define the 
potential impact of chronic RhCMV infection on the host immune system. My role was to 
investigate the immune development during the first year of life. Access to infant human 
samples in infants is extremely limited, so our lab took advantage of the rhesus macaque 
model to define normal immune development from birth to 1 year of age. The NHP model 
enabled us to collect longitudinal blood samples and document changes in frequencies and 
maturation of various lymphocyte populations. In this study, I was able to document CD4+ T 
cell development during the first year of life. I showed that although IFNγ responses were 
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drastically reduced in CD4+ T cells at birth, they gradually increased during the first year, 
consistent with the transition of naïve CD4+ T cells to effector and effector memory T cells. 
Interestingly, frequencies of CD8+ T cells producing IFNγ were similar from birth throughout 
the first year of life. Therefore, my data indicated that IFNγ production by infant CD4+ T 
cells is perhaps restricted by CD4+ T cell-intrinsic factors. In the fight against infectious 
diseases, it is important to know when CD4+ Th1-IFNγ responses mature because such 
responses are critical in the clearance of most intracellular pathogens. In fact, it is this lack of 
Th1 responses that results in the Th2 bias of the infant immune response. Thus, determining 
the time frame during which Th1 responses mature in infants will have great implications in 
vaccine designs, implementation strategies and immunization schedules. Our longitudinal 
studies were a first step in this process.  
The significance of these findings was underlined by an in vivo RhCMV-infection 
study. Chapter 3 described the data we found on a smaller longitudinal study following 
experimentally RhCMV-infected infant and adult animals. Our goal was to establish an oral 
infection model of RhCMV in infant macaques to model oral HCMV acquisition by breast 
milk or by contact with saliva in human infants. My data showed that infant monkeys were 
easily infected after a single exposure, whereas 2 of 3 adult macaques required multiple 
exposures of RhCMV via the oral route. Moreover, RhCMV-infected infant monkeys had 
decreased ability to control viral replication as they frequently shed RhCMV in saliva and 
urine while adult monkeys only transiently shed the virus in the same compartments. Lack of 
viral control might be the result of insufficient immune response in infants as best illustrated 
by the rapid progression of HIV-infected infants compared to adults (Prendergast Andrew 
2012). Our work in the NHPs made it possible to study the interplay of age and a chronic 
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viral infection in the development of the immune system and allowed us to study viral 
pathogenesis in infants from birth to 1 year of age. 
In the same study, Chapter 2 also evaluated juveniles and adult macaques of SPF and 
non-SPF status, where non-SPF animals were naturally infected with RhCMV. We wanted to 
determine how the function of the immune system is perturbed by the presence of RhCMV. 
We found that age-related changes in immune cell populations in the peripheral blood were 
common in animals regardless of SPF status. Moreover, frequent shedding of RhCMV in the 
bodily fluids was more readily detected in non-SPF juvenile compared to adult monkeys. 
RhCMV infection appeared to influence the maturation of both T and B cells and altered T 
cell responsiveness. Compared to adult monkeys, non-SPF juveniles showed a propensity 
towards higher inflammatory cytokine production after specific and non-specific stimulation. 
Lifelong exposure to inflammatory cytokines due to a chronic viral infection like RhCMV or 
HCMV in humans could affect the generation of effective immunity against novel pathogens 
and increase the host’s susceptibility to tissue damage. Rhesus macaques could serve as a 
valuable tool to model certain immunological alterations such as immunosenescence and 
“inflammaging” in relation to the host’s age, health and disease status.  
I have determined that IFNγ response in infant rhesus monkeys increase throughout 
the first year of life (Chapter 2) and I indirectly showed the importance of Th1- IFNγ 
response in RhCMV control in infants (Chapter 3). Given these findings, I wanted to know 
whether comparable and supporting data regarding potential mechanisms could be observed 
in human infants. Specifically, I was interested in determining the mechanisms that control 
IFNγ responses and the factors important for Th1 differentiation. Chapter 4 followed up on 
the above findings and took them a step forward by asking whether infant CD4+ T cells could 
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respond to exogenous IFNγ. These studies were done with human infant blood samples. I 
performed a detailed analysis of the components of the IFNγ signaling pathway to evaluate 
both IFNγ responses and the factors involved in Th1 differentiation. My results clearly show 
that activation of the IFNγ signaling pathway in infant CD4+ T cells is reduced at multiple 
levels and is significantly lower compared to adult CD4+ T cells. This reduced response was 
not due to lack of IFNγ receptor expressing CD4+ T cells, but was due to reduced activation 
of the JAK2 kinase and the transcription factor STAT1. I was able to demonstrate though that 
signaling defects can be overcome by 2-5 months of age. In contrast, I could show that IL4 
signaling was not impaired. Unexpectedly, I also determined that infant CD4+ T cells show a 
drastically reduced response to IL2. In fact and in contrast to IFNγ, IL2 signaling still 
resulted in lower activation of the relevant transcription factor STAT5 by 1 year of age. I 
obtained similar data for IL7, another important T cell growth factor.  
Though not covered in this thesis work, I contributed significantly to a project that 
tested the safety and immunogenicity of a novel pediatric combination vaccine with the goal 
to prevent HIV/SIV and TB infection in infants. The vaccine was found to induce both SIV 
and TB-specific immune responses in infant rhesus macaques. My work was acknowledged 
by being a 2nd author on a resulting publication (64).  
SIGNIFICANCE 
Research data regarding cytokine signaling in the developing infant have been limited 
and the data available have not thoroughly explored such signaling pathways in infant CD4+ 
T helper cells and subsets (102). The data from this work provided evidence that during 
infancy, there are intrinsic factors (e.g. cytokine signaling) underlying the reduced 
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performance of infant immune cells (e.g. CD4+ T cells) in generating effective immunity 
against intracellular pathogens. From birth, adulthood and to aged, the host’s immune system 
has to strictly balance pro and anti-inflammatory cytokines to effectively deal with infectious 
pathogens and avoid detrimental damage to the host’s tissues. Identifying and targeting the 
elements that contribute to the reduced immune responsiveness of infants are important to 
protect these young hosts from infectious diseases. When the host is aged, the overall 
performance of the immune system is changed leaving the host susceptible to novel 
pathogens and tissue pathologies. At these extreme stages of life, understanding the intricate 
network of factors that shape the immune responses in the infant and aged environment will 
be imperative in optimizing vaccines and targeted therapeutic strategies.  
REMAINING QUESTIONS AND FUTURE DIRECTIONS 
 More longitudinal and comparative studies are still needed in defining the exact 
mechanisms leading to distinct immune responses of infants compared to adults.  Specifically, 
in Chapter 2, some of the questions worth examining are (i) Do chronic infections such as 
HCMV/RhCMV result in T and B cell changes at the molecular level? (ii) Can these changes 
be detected early and corrected through therapeutic means? (iii) Importantly, in humans, are 
there genetic markers that can identify aged people that are at risk for “inflammaging”? And 
lastly, (iv) what triggers RhCMV reactivation in the young and old? In Chapter 3, we 
described that infants were more susceptible to RhCMV infection via the oral route. What 
host immune factors in the infant oral cavity are involved in increasing RhCMV 
susceptibility? Similarly, what immune responses or lack thereof are responsible for the 
persistent viral replication in certain body compartments (e.g. oral and urogenital tract)? Such 
questions are still open for exploration. We also expect that increasing our animal numbers 
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and choosing a more appropriate age group that best represent adult humans will offer 
significant differences in the quality and magnitude of RhCMV-specific responses. The 
findings in cytokine signaling presented in Chapter 4 are incomplete because differences in 
phosphorylation of the relevant JAK kinase for IL4 and IL2 in infant and adult CD4+ T cells 
have not been evaluated. Efforts in measuring JAK1 phosphorylation after IL4 or IL2 
treatment are underway in the lab. Increasing our sample numbers between birth and 1 year 
of age will be critical in defining time frames when infant CD4+ T cells will be functionally 
competent as adults.  
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Figure 1: Graphical representation of infant immunity. This picture highlights the 
dynamic relationship of age and the maturity of the immune system in infectious disease 
control. A. Disease susceptibility of infants decreases with age as immune function increases. 
B. Distinct viral pathogenesis are observed between HIV and HCMV/RhCMV because the 
latter is rarely fatal and overall infant health is preserved (depicted by the shaded area) unless 
infection was acquired in utero or under immune suppression* C. As infants become older, 
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the frequency of naïve CD4+ T cells decreases overtime with concurrent increase of memory 
CD4+ T cells, consistent with increasing antigen exposure with age. D. Age-dependent 
maturity of the components of IFNγ, IL2, and IL4 signaling are critical for the proper 
development and function of effector CD4+ T cells to effectively combat infectious diseases.  
 
CONCLUDING REMARKS 
Fine-tuning in the components of the immune system must be achieved to 
successfully face the unique challenges encountered at different stages of life. My thesis 
work focused on evaluating the functional properties of CD4+ T cells early in life and how 
their function changes in relation to age (Figure 2). My studies found that age-related 
differences are detected in the infant and adult CD4+ T cell development, maturation, 
function and signaling in normal setting. Perturbations, such as caused by viral infections, 
will likely affect these processes. It is of great interest to understand the dynamic relationship 
between age and CD4+ T cell immunity to identity which immune parameters in infants can 
be used as “immune signatures” to evaluate vaccines and therapeutics as means to develop 
appropriate and effective immune function.  
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